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Zoledronic acid is a nitrogen-containing bisphosphonate widely used in the 
treatment of bone metastasis secondary to breast cancer. In addition, 
current clinical trials suggest direct antitumor effects, which may reduce 
the risk of overall disease progression in breast cancer patients. 
Consistently, recent experimental approaches have demonstrated strong 
antiproliferative and apoptotic effects in various human cancer cells, 
although the molecular mechanisms remained elusive.  
 
This study was conducted to identify key mechanisms underlying the 
growth suppressor activity of zoledronic acid in epithelial cancer. For this 
purpose, we employed an extensive series of cellular, molecular as well as 
biochemical studies and uncovered the existence of a nuclear GSK3β-
NFATc2 stabilization pathway that is target for inactivation by zoledronic 
acid during growth suppression. GSK3β labels nuclear NFAT through 
phosphorylation of three phosphoserines (Ser 215, Ser 219 and Ser 223) 
residues located within the N-terminal SP2 motif of the factor, and this 
post-translational modification protects the factor from ubiquitination and 
degradation. The phosphoserine sequences are highly conserved among 
species and are identical to the previously reported “phospho-degron” 
elements through which GSK3β labels other key cell cycle regulators for 
subsequent ubiquitination and proteasomal degradation.  
 
Here, we show that GSK3β can make use of the “phospho-degron” 
elements to stabilize rather than proteolyse mitogenic transcription 
factors, and thus GSK3β exerts pro-proliferative functions through 
stabilization of NFATc2 levels in cancer. Treatment with zoledronic acid, 
however, inhibits GSK3β kinase activity, thus disrupts NFATc2 




proteasomal machinery to target NFATc2 for degradation. Mechanistically, 
HDM2, the human homologue of the E3-ligase MDM2, accumulates in the 
nucleus upon treatment binds to NFATc2 and transfers ubiquitin to lysines 
K-684 and K-897. Ubiquitination of K-684 and K-897 requires an 
unphosphorylated status of NFATc2 in the nucleus and is key for the 
subsequent recognition and degradation by the 26S proteasome. The net 
cellular outcome of GSK3β -NFATc2 pathway disruption and degradation of 
the transcription factor is a progredient halt of cancer cells at the G1 cell 
cycle phase.  Together, this study uncovers a key pathway in cancer growth 
control that is aimed for inactivation by zoledronic acid. From the medical 
point of view, we believe that these findings significantly contribute to a 
better understanding of the biochemical basis underlying one of the most 





Bisphosphonate gehören zur Standardtherapie verschiedener 
Erkrankungen, die mit einem gesteigerten Osteoklasten-Stoffwechsel und 
einem Abbau der Matrix einhergehen. Hierzu zählen neben der  
Behandlung einer Osteoporose, des Morbus Paget und des malignen 
Myeloms v.a. osteolytische Metastasen des Brustdrüsenkrebses und 
anderer epithelialer Tumore. Darüber hinaus belegen Arbeiten der letzten 
Jahre eine starke anti-tumoröse Wirkung v.a. neuer Bisphosphonate wie 
z.B. Zoledronsäure, die auf einer direkten Beeinflussung der Tumorzellen 
beruhen. In vitro und in vivo Studien belegen eine ausgeprägte 
antiproliferative Funktion von Zoledronsäure in verschiedenen 
Tumormodellen, obgleich die zugrundeliegenden Mechanismen nur 
unzureichend verstanden sind. Im Rahmen der vorliegenden Untersuchung 
wurden in einem kombinierten in vitro/ in vivo Modell die molekularen 
Mechanismen der Zoledronsäure vermittelten Tumorsuppression im 
Pankreas- und Mammakarzinom analysiert. Dabei konnten wir einen 
interessanten Wirkmechanismus identifizieren und zeigen, dass 
Zoledronsäure durch Inaktivierung einer GSK3β-abhängigen NFATc2 
Stabilisierung dessen proteasomalen Abbau induziert. NFATc2 ist ein 
zentraler Regulator der Zellzykluskontrolle und stimuliert durch 
transkriptionelle Regulation von Zyklinen und deren Aktivatoren die G1-
Zyklus Progression in Tumorzellen. Aktives NFATc2 wird entsprechend 
unserer Ergebnisse im Zellkern von Tumorzellen durch GSK3β 
phosphoryliert und vor einer Ubiquitinylierung und Degradation geschützt. 
Dabei erkennt und phosphoryliert GSK3β drei Serinstellen innerhalb der N-
terminalen SP2-Domäne. Zoledronsäure führt zur Hemmung von GSK3β im 
Zellkern und verhindert somit die schützende Phosphorylierung von 
NFATc2. Darüber hinaus induziert Zoledronsäure die nukleäre 




dessen C-Terminus (K-684 und K-897) ubiquitinyliert und für die 
nachfolgende proteasomale Degradation markiert. Zusammenfassend 
führten diese Untersuchungen zur erfolgreichen Identifikation eines 
zentralen Mechanismus der Zoledronsäure induzierten 
Wachstumshemmung, die auf der Inaktivierung eines wichtigen 
onkogenen Signalweges (GSK3β-NFATc2) beruht. Aus molekularer Sicht 
sind diese Ergebnisse von groβem Interesse, da sie einen bislang 
unbekannten Regulationsmechanismus der NFAT-Transkriptionsfaktoren 
beschreiben und zu einem besseren Verständnis dieser onkogenen 
Transkriptionsfaktoren in der Tumorbiologie beitragen. Noch relevanter 
dürften unsere Erkenntnisse allerdings aus medizinischer Sicht sein, da sie 
den Nutzen von Zoledronsäure in der Tumortherapie epithelialer 
Krebserkrankungen unterstützen und deren Wirksamkeit durch 




















The potential to inactivate osteoclastic bone resorption makes the third 
generation bisphosphonate zoledronic acid an attractive agent in the 
treatment of benign and malignant skeletal diseases related with increased 
bone loss, e.g. Paget’ disease, osteoporosis and metastasis related 
osteolysis (Rodan et al., 2002; Russell et al., 1999). The beneficial effect of 
zoledronic acid in the treatment of advanced cancer diseases with 
osteolytic bone metastasis has extensively been demonstrated and led to a 
widespread use of the compound in those patients (Hughes et al., 1995). 
Over the past decade, zoledronic acid has become the standard therapy for 
breast cancer patients with established metastasis in the bone (Costa et al., 
2007; Body et al., 2003). In addition to its well characterized effects on 
skeletal metastasis, increasing evidence from preclinical and clinical trials 
emphasize strong anti-tumor functions of the drug that work outside the 
bone and directly target the tumor cells, resulting in inhibition of tumor 
outgrowth, reduced incidence of visceral metastasis, and increased overall 
survival (Boissier et al., 2000; Pluijm et al., 1996).  
 
A new milestone in breast cancer therapy was recently achieved by an 
international multi-center study in early stage cancer patients, reporting a 
dramatic reduction of local tumor recurrence after surgery, when 
endocrine therapy was combined with zoledronic acid (Gnant et al., 2009). 
Consistent with the clinical data, in vitro and in vivo studies identified 
substantial growth suppression activities of zoledronic acid in breast and 




1.2 CHEMISTRY AND STRUCTURE OF 
BISPHOSPHONATES 
Bisphosphonates (BPs) are synthetic nonhydrolyzable analogues of the 
naturally occurring pyrophosphate molecule. Pyrophosphate (PPi) is 
produced by many anabolic processes and rapidly hydrolysed to its two 
constituent phosphate groups. A bisphosphonate is formed when the 
linking oxygen atom in the pyrophosphate molecule is replaced by a carbon 
atom. Therefore, these analogues are completely resistant to hydrolysis 
and are chemically extremely stable for binding to the hydroxyapatite 
crystals of bone and prevent both their growth and their dissolution.  
 
The biological activity of the bisphosphonates can be modified by altering 
the structure of the two side chains on the carbon atom and those two 
chains (referred to as R1 and R2) are covalently bound to the carbon atom 
of the common P–C–P structure. In addition, binding to bone mineral 
depends upon the P-C-P structure and is enhanced by including a hydroxyl 
group at R1, allow BPs to bind to bone mineral.  
 
The structure and three-dimensional configuration of the R2 side chain 
determines the cellular effects of bisphosphonates (Fig. 1), and their 
relative efficacies as inhibitors of bone resorption as well as that imparts
 
the ability to bind divalent metal ions, such as Ca
2+
. For this cause, BPs are 
rapidly cleared from the circulation (Russell et al., 1999). BPs, such as 
etidronate, clodronate or tiludronate, which lack a nitrogen functional 
group in R2 chain, inhibit essential ATP-dependent intracellular enzymes 
which leads to an intracellular accumulation of cytotoxic ATP-analogues ( 






Fig. 1. Basic chemical structure of Bisphosphonates. The two phosphonate (PO3) groups 
covalently linked to carbon determine both the name "bisphosphonate" and the function 
of the drugs. The long  side chain (R2 in the diagram) determines the chemical properties, 
the mode of action and the strength of bisphosphonate drugs. The short side chain (R1), 
often called the 'hook', mainly influences chemical properties and pharmacokinetics. 
 
 
Nitrogen-containing bisphosphonates or amino bisphosphonates, such as  
zoledronic acid are more potent at inhibiting bone resorption 
 
in vivo. The 
increased inhibitory potency  of N-BPs results from structural differences 
that affect anti-resorptive capacities of the drug (e.g., pamidronate, 
risedronate, alendronate, minodronate, ibandronate and zoledronate or 
zoledronic acid). The most potent bisphosphonates are those containing a 







Fig. 2. Chemical structures of Nitrogen-containing bisphosphonates. Structure
 
and 
conformation of the R
2
 side chain of Nitrogen-containing bisphosphonates (adapted from 








1.3 MOLECULAR MECHANISMS OF ACTION OF 
NITROGEN-CONTAINING BISPHOSPHONATES  
Nitrogen-containing bisphosphonates act by inhibiting farnesyl 
pyrophosphate synthase (FPPS). Among these BPs, zoledronic acid and
 
the 
structurally similar minodronate are extremely potent inhibitors
 
of FPPS 
and inhibit the enzyme even at picomolar
 
concentrations in osteoclasts 
(Dunford et al., 2001) (Fig. 3). FPPS is a key regulatory enzyme in the 
mevalonate pathway. This pathway, ubiquitous in mammalian cells, 
provides essential lipid molecules, such as cholesterol and isoprenoids, 
with the later necessary for post-translational prenylation of small 
GTPases, such as those of the Ras, Rho, Rac, Rab and Cdc42 (Rogers et al., 
2003; Dunford et al., 2001; Coxon et al., 2003). These proteins are major 
players in a variety of cellular processes that are required for osteoclast 
functions.  
 
Blocking this pathway by using N-BPs, induce severe morphologic changes 
in osteoclasts and interfere with various intracellular processes such as 
cytoskeleton reorganization, vesicle transport, exocytosis and ultimately 
leading to apoptosis (Coxon et al., 2003). Inhibition of the mevalonate 
pathway and loss of prenylated
 
proteins, particularly geranylgeranylated 
small GTPases, seem
 
to be the major mechanism of action of N-BPs in 
osteoclasts because bypassing
 
inhibition of FPP synthase and replenishing 
cells with an isoprenoid
 
lipid substrate that restores geranylgeranylation 
can overcome
 
the effects of N-BPs on osteoclast formation, apoptosis, and
 
bone resorption (Reszka et al., 1999; Fisher et al., 1999; van Beek et al., 
2003). The blockade of this pathway is a concept that has found 
widespread clinical use, with statins as drugs that inhibit HMG-CoA 
reductase (HMGCR) and reduce cholesterol biosynthesis, and nitrogen-
containing bisphosphonates (N-BPs) as drugs for osteoporosis therapy that 




FPP synthase inhibition in osteoclast might also play a central role in bone 
metastasis (Clezardin et al., 2005; Dunford et al., 2001). Infact, several 
reports suggest that FPPS inactivation probably via modification of the 
bone matrix affect the ability of tumor cells to infiltrate the bone and to 
establish metastasis (Sasaki et al., 1998; Sasaki et al., 1999; Green et al., 
2000). In contrast, only very scarce information is available in the literature  
showing how bisphosphonates affect the tumor cells (see detailed 
information below). The current literature however, suggest that BPs such 
as zoledronic acid primarily target signaling and transcription pathways 
other than the FPPS system outside the bone metabolism.  
 
 
Fig. 3. Mechanisms of action of Nitrogen-containing bisphosphonates. 3-hydroxy 3-
methylglutaryl-CoA (HMG-CoA) is converted to mevalonate by HMG-CoA reductase, the 
rate-limiting enzyme at the apex of the mevalonate pathway. Mevalonate is then 
converted to isopentyl pyrophosphate (isopentyl-PP; the 5-carbon basic isoprene unit), 
which is subsequently converted to farsenyl pyrophosphate (farsenyl-PP; a 15-carbon 




farsenyl-PP can be converted to geranylgeranyl pyrophosphate (geranylgernayl-PP; a 20-
carbon isoprenoid), or alternatively farsenyl-PP can be converted to cholesterol or dolichol 
phosphate (dolichol-P), which is used for N-glycosylation of growth factor receptors such 
as insulin-like growth factor receptor. HMG-CoA reductase is the target of the cholesterol-
lowering statins, whereas isopentenyl-PP isomerase and farsenyl-PP synthase are targets 
of bisphosphonates (adapted from Panagiotis et al., 2005) 
 
1.4 ANTI-TUMORIGENIC FUNCTIONS OF 
ZOLEDRONIC ACID 
Numerous approaches using diverse tumor types and models have been 
used to elucidate the effects of zoledronic acid, and other N-BPs, on tumor 
cells and their interaction with surrounding structures, apart from those 
mediated by osteoclast activity. Increasing evidence is accumulating that N-
BPs are able to directly affect tumor cells. For instance, it has been shown 
that N-BP inhibit cell proliferation in myeloma, breast, prostate, skin and 
pancreatic cancer, in a concentration- and time-dependent manner 
(Shipman et al., 1997; Tassone et al.,  2002; Clezardin et al., 2005 et al., 
Ying-Ying Lia et al., 2008;  Sewing et al., 2008;  Rachner et al., 2009). 
 
 The pioneering studies by Shipman et al. were the first to demonstrate 
direct antitumor activity of bisphosphonate in myeloma cell lines (Shipman 
et al., 1997; Shipman et al., 1998) and these promising studies were 
subsequently confirmed and extended by other groups using different 
models and different members of the bisphosphonate family (Aparicio et 
al., 1998). Overall the results clearly demonstrated that zoledronic acid 
reduces cell proliferation in epithelial tumors through induction of a cell 
cycle arrest and  initiation of programmed cell death, called apoptosis. In 
some tumor cells, the growth inhibiting effect of bisphosphonates can 
partially be rescued through  adding of geranylgeraniol and farsenyl, two 
intermediates of the mevalonate pathway (Shipman et al., 1998), although 




pathways that confer growth inhibition upon treatment with 
bisphosphonates. Similar to the situation in melanoma cells, BPs have been 
shown to block proliferation in breast and pancreatic cancer in vitro 
(Senaratne et al., 2000; Tassone et al., 2002), through aiming on the cell 
cycle machinery  (Benassi et al., 2007; Sewing et al., 2008; Romani et al., 
2009). The third generation nitrogen containing BPs, zoledronic acid has 
proven to be the most attractive and potent inhibitor of tumor cell 
proliferation. In addition, it also affects tumor cell migration and  invasion 
in different systems (Magnetto et al., 1999; Boissier et al.,  2000; Virtanen 
et al.,  2002). 
  
Recently, considerable progress have been made in elucidating the anti-
tumorigenic functions of N-BPs in animal models. The potent N-BPs have 
been shown to inhibit skeletal metastasis and reduce
 
tumor burden in 
animal models of breast, lung and prostate cancer (Green et al., 2004; 
Giraudo et al., 2004; Croucher et al., 2003; Santini et al., 2003; Santini et 
al., 2006). In addition, it also decreases the release of tumor-promoting 
growth factors from bone by inhibiting osteoclast-mediated bone 
resorption (Hall et al., 1994; Alvarez et al., 2000; Duivenvoorden et al., 
2007; Florence et al., 2007; Ottewell et al., 2008; Lia et al., 2007; Stearns et 
al., 1996; Pollar et al., 1985; Corey et al., 2001). 
 
 A separate but equally important phenotype in carcinoma progression is 
invasive migration, a process which eventually leads to metastatic 
dissemination of tumor cells to distant organs. Recent studies suggested 
that, zoledronic acid blocks tumor cell proliferation and migration of breast 
cancer cells in immunocompromised mice (Green et al., 2004; Giraudo et 
al., 2004; Croucher et al., 2003; Santini et al., 2003; Santini et al., 2006; 
Holen et al., 2009; Clezardin et al., 2005; Korpal et al., 2009). Recently, it 
has also been shown that zoledronic acid inhibits tumor growth and 




a xenograft  mice model (Caraglia et al., 2006). Importantly, several new 
studies provide evidence for additive or synergistic apoptotic effects of 
zoledronic acid in combination with a variety of standard anti-neoplastic 
agents, including paclitaxel, gemcitabine and doxorubicin (Jagdev et al., 
2001; Ullen et al., 2003;  Neville et al., 2005; Vogt et al., 2004; Matsumoto 
et al., 2005). For instance, sequential treatment with doxorubicin followed 
by zoledronic acid inhibited the growth of subcutaneous breast tumors in 
vivo (Ottewell et al., 2009). It has also been shown that zoledronic acid 
possess synergistic anti tumorogenic activity in combination with imanitib 
and paclitaxel by substantially improving the survival of mice bearing 
prostate and breast cancer cells (Kim et al., 2005). 
 
Together, there is now growing evidence indicating that bisphosphonate 
and particularly zoledronic acid can directly target the tumor cell to 
suppress cancer growth, alone or in combination with chemotherapy.    
 
 1.5 ZOLEDRONIC ACID AND THE CELL CYCLE 
MACHINERY 
Depending on the tumor type, zoledronic acid has been shown to disrupt 
cell cycle progression in tumor cells at various stages. The mammalian cell 
cycle consists of four phases, designated G1, S, G2 and M phase (Norbury 
et al., 1992). During each cell cycle, the complete genome is duplicated in S 
phase (the synthetic phase), and subsequently the two copies divided over 
two daughter cells in M phase (mitotic phase). Authorization for DNA 
synthesis and chromosomes segregation is tightly controlled by cyclins and 
their associated kinase activities that become active during the gap-phases 
G1 and G2, proceeding S and M phase, respectively (Fig. 4) (Nurse et al., 
1999). D-type cyclins and their partners kinases CDK4 and CDK6 are key 




essential for entry from G2 into M phase. These cyclins are well known 
targets of mitogenic and anti-mitogenic input signals, which can stimulate 
or block cell cycle progression. An important barrier to limitless 
proliferation is raised by a cell cycle control mechanism that prevents G1/S 
transition (heart of the cell cycle machinery) in response to growth-
inhibiting stimuli like differentiation, DNA damage, oncogene, oncogene 
activation, loss of anchorage, confluency or mitogen deprivation. Loss of 
G1/ S control clearly is a mandatory step in tumor development and is 
associated with imbalanced and uncontrolled cell proliferation 
(Dannenberg et al., 2004). Recently, It has been also suggested that 
zoledronic acid can act at different levels and cell cycle stages. For instance, 
a profound cell cycle arrest in G2 phase was seen in osteosarcoma cells 




Fig. 4. Schematic representation of cell cycle. This simplified schematic representation of 
the cell cycle includes the main molecular participants that are involved in cell-cycle 






However, most recent evidence also suggests that zoledronic acid 
particularly affects the G1 cell cycle phase and impairs progression to the 
DNA replicating S-phase in epithelial cancer (Fromigue et al., 2000; 
Jonathan et al., 2003). In fact, it has been shown that zoledronic acid 
targets colon cancer cells at G1 and blocks progression of the cell cycle 
(Sewing et al., 2008). Together, the current literature is not yet conclusive 
and therefore, detailed analysis are required to elucidate how zoledronic 
acid targets the cell cycle in a tumor specific manner.  
 
1.6 THE NFAT FAMILY OF TRANSCRIPTION FACTORS 
Cell cycle progression is tightly controlled by the action of mitogenic and 
anti-proliferative signaling and transcription pathways. Among others, the 
NFAT transcription factor family has key functions in cell cycle stimulation 
and not surprisingly exerts pro-proliferative activities in a variety of 
cancers.  The nuclear factor of activated T cells (NFAT) signaling axis is a 
vertebrate-specific signaling and transcription pathway that controls 
various vital cellular functions through its ability to regulate gene 
expression (Crabtree et al., 2002; Im et al., 2004). The canonical NFAT 
pathway, first elucidated in immune cells, is activated through a raise in 
intracellular calcium through either increased flux from endoplasmic 
reticulum stores or activation of store-operated channels in the plasma 
membrane (Crabtree et al., 1999; Crabtree et al., 2002). In the basal state, 
NFATs are hyper-phosphorylated in the cytoplasm. Subsequent to cell 
stimulation and calcium release, NFATs are dephosphorylated by the 
phosphatase calcineurin and translocate to the nucleus (Luo et al., 1996), 
where they co-operate with other factors and co-activators to promote de 
novo gene transcription.  
 
The foundation of the NFAT research field was based on the original 




interleukin-2 (IL-2) promoter during the activation of T cells (Shaw et al., 
1988). The importance of NFAT signaling is also highlighted by the fact that 
immunosuppressants such as cyclosporin A (CsA) and FK506, which 
specifically inactivate the canonical NFAT pathway, are widely used in the 
clinic to prevent organ transplant rejection. Since their discovery two 
decades ago, it has become increasingly clear that NFAT transcription 
factors are expressed not only in immune cells but in all cells and tissues 
(Crabtree et al., 2002; Im et al., 2004). In this context, several recent key 
findings have pointed to important roles for NFATs in modulating 
phenotypes associated with malignancy and tumor progression (Jauliac et 
al., 2002; Yoeli-lerner et al., 2005). NFAT isoforms are  overexpressed in 
human solid tumors and haematological malignancies and seem to have 
roles in cancer cell-autonomous functions such as proliferation, invasive 
migration, differentiation and the survival of cells in the tumor and its 
microenvironment (Jauliac et al., 2002; Buchholz et al., 2006). It is thought 
that understanding the parts played by NFATs in tumor progression will 
help the development of effective therapeutics that target the NFAT 
pathway in cancer progression and metastasis. In fact, overexpression of 
NFAT have been described in various human breast, colon and pancreatic 
cancers and cell lines, and in particular in those with a aggressively growing 
phenotype (Jauliac et al., 2002; Chen et al., 2005; Yiu et al., 2006; Buchholz 
et al., 2006). NFATc1 and NFATc2 regulate the expression of cell cycle 
promoting genes as well genes that stimulate angiogenesis, migration and 
invasion, and thus targeting of these factors might be a promising new 
strategy in cancer (Caetano et al., 2002; Baksh et al., 2002; Graef et al., 
2003; Buchholz et al., 2006).  
 
Based on these findings in tumor diseases, one would predict that as 
potent calcineurin–NFAT inhibitors, both CsA and FK506 could be effective 
cancer therapeutics. Somewhat paradoxically, there is actually a significant 




treatments (Dantal et al, NEJM 2005). The explanation for this observation 
is twofold: first, the increased cancer incidence is probably due to 
decreased immune surveillance; second, other targets of calcineurin exist 
that function to modulate phenotypes associated with cancer, such as 
proliferation and survival. Moreover systemic administration of CsA and 
FK506 would affect the entire milieu of the tumor microenvironment, with 
pleiotropic effects on cellular pathophysiology. It is more reasonable to 
assume that effective NFAT therapy in cancer will have to come from 
targeted therapy for the tumor endothelium or the tumor cells themselves, 
as these are the primary compartments in which attenuation of NFAT 
activity is predicted to block or even reverse the tumorigenic phenotype.  
 
Aims of the study 
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2 AIMS OF THE STUDY 
Bisphosphonates are proven to be effective in the treatment of benign or 
malignant skeletal diseases characterized by enhanced osteoclastic bone 
resorption. Nitrogen-containing bisphosphonates have also been 
demonstrated to exhibit direct anti-tumor effects. They not only inhibit 
proliferation and induce apoptosis in cultured cancer cells, but also 
additionally interfere with adhesion of cancer cells to the bone matrix and 
inhibit cell migration and invasion. Zoledronic acid is a highly potent N-BP 
that has been particularly well investigated, preclinical and in clinical 
practice. Growing preclinical evidence shows that zoledronic acid also 
exhibits direct anti-tumor activity in breast and other tumor of epithelial 
origins. 
The overall effects on tumor cells appear to be mediated via diverse 
pathways, such as growth inhibition, cell cycle arrest and apoptosis. 
However, the molecular mechanisms underlying zoledronic acid mediated 
anti-tumor effects are only partially understood. 
In previous work, we have demonstrated the pro-proliferative functions of 
NFAT transcription factors in cancer. Here, we questioned whether and 
how zoledronic acid targets the NFAT signaling and transcription pathway 
to mediate its growth suppressor function in breast and pancreatic cancer.  
In particular, we addressed the following questions: 
1. Does zoledronic acid suppress tumor growth in vitro and in vivo? 
2. Does zoledronic acid target the oncogenic NFATc2 pathway in 
cancer cells? 
3. Does zoledronic acid interfere with NFAT activity, distribution and 
stability in cancer? 
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3 MATERIALS AND METHODS 
 
3.1 MATERIALS 
3.1.1 Mice  
 
6 to 8 weeks old pathogen-free female athymic nu/nu mice were obtained 
from Harlan Winkelman (Harlan Winkelman GmbH, Borchen, Germany). 
They were kept in the animal care facility of University hospital of Marburg, 
institutional guidelines were followed in handling mice throughout the 
course of the study. 
 
3.1.2 Cell lines 
 
The list of cell lines used in this study: 
 
1. MDA-MB-231 (Breast cancer cell line)  
2. MDA-MB-435 (Breast cancer cell line) 
3. MDA-MB-468 (Breast cancer cell line) 
4. IMIM-PC-1 (Pancreatic cancer cell line) 
5. PaTu8988t (Pancreatic cancer cell line) 
 
3.1.3 General Materials  
 
Reagent      Source  
Cell strainer (70 μl)    Greiner bio-one 
2 ml cryotubes     Greiner bio-one  
Disposable needles, cuvettes & syringes Greiner bio-one 
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Glassware     Schott 
Nitrocellulose membrane   Schleicher & Schuell  
Polypropylene tubes    Greiner bio-one  
Parafilm      Greiner bio-one  
Pipette tips     Eppendorf  
Pipettes      Sarstedt  
Röntgen film (13x18 cm, BioMax)  Kodak  
Sterile filters (0.2 μM/ 0.45 μM)  Schleicher & Schuell  
Tissue culture plates    Greiner bio-one  
Tissue culture flask (50, 250, 500 ml)  Greiner bio-one  
Tissue culture dish (60 mm, 90 mm)   Greiner bio-one  
Tubes (1.5 & 2 ml)     Eppendorf  
Whatmann paper    Schleicher & Schuell  
12 well cell culture plates   Cellstar 
6 & 24 well cell culture plates   Cellstar 
6 mm Petri dishes    Cellstar 
T-25, T-75 & T-250 tissue culture flasks Nunc 
 
3.1.3.1 Chemicals and Reagents  
 
Name of the chemical s   Source  
Acetone      Carl Roth  
Acrylamid solution    Carl Roth  
Agar-Agar     Carl Roth  
Agarose      Sigma-Aldrich  
Ampicillin     Hoechst  
APS Merck     Eurolab  
β-mercaptoethanol    Carl Roth  
BioRad protein assay    BioRad  
Bromophenol blue    Eurolab 
Bovine serum albumin (BSA)   Sigma  
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Calcium chloride    Carl Roth  
Complete protease inhibitor   Roche 
ECL chemiluminescence kit   Pierce 
dNTPs      MBI-Fermentas  
DTT      Carl Roth  
ECL Chemiluminiscence Kit   Roche  
EDTA      Carl Roth  
EGTA      Sigma-Aldrich  
Ethanol      Carl Roth  
Ethidium bromide    Sigma-Aldrich  
Formaldehyde     Carl Roth  
Forskolin     Calbiochem  
ECL chemiluminescence kit   Pierce 
Gene Ruler™ 100bp ladder   MBI Fermentas 
Glycerin (87%)     Carl Roth  
Glycine      Carl Roth  
Hepes      Carl Roth 
Hydrochloric acid    Merck  
Isoamylalcohol     Carl Roth 
Isopropanol     Carl Roth 
Leupeptin hydrochloride   Roche  
Milk powder     Sigma 
Magnesium acetate    Sigma-Aldrich 
Magnesium chloride    Carl Roth 
Magnesium sulfate    Carl Roth 
Manganese chloride    Fluka 
Methanol     Carl Roth 
PCR purification kit    Qiagen 
Phenol [C6H6O, TE equilibrated]  Carl Roth 
Plasmid-DNA isolation kit (Maxi)  Qiagen 
PMSF      Serva 
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Proteinase K     SIGMA-Aldrich 
Protein A sepharose    Upstate 
Protein G sepharose    Upstate 
Polyacrylamide     Applichem 
Ponceau Red     Sigma Aldrich 
Potassium acetate    Carl Roth 
Potassium chloride    Sigma-Aldrich 
Potassium dihydrogen phosphate  Sigma-Aldrich 
Potassium hydrogen phosphate  Sigma-Aldrich 
Potassium hydroxide     Carl Roth 
Propidiumiodide    Sigma Aldrich 
Protease inhibitor tablet (complete mini) Roche  
Sodium azide     Sigma 
Sodium citrate     Sigma       
Sodium chloride    Roth 
Sodiumdodecyl sulfate (SDS)   Roth 
Sodium acetate     Merck Eurolab 
Sodium carbonate    Carl Roth 
Sodium chloride    Carl Roth 
Sodium fluoride    Sigma-Aldrich 
Sodium hydrogen phosphate   Merck Eurolab 
Sodium hydroxide    Carl Roth 
TEMED      Carl Roth 
Tris      Carl Roth 
Triton X-100     Aldrich 
Tween 20     Carl Roth 
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Drug      Source  
Zoledronic acid (ZOL)    Novartis-Pharma  
[2-(imidazol-1-yl)-hydroxy-ethylidene-1, 
1-bisphosphonic acid, disodium salt, 
 4.75 hydrate] 
 
Radioactive chemical     Source 
[methyl-
3






Hardware     Manufacturer  
Autoclave     Stiefenhofer  
Bacterial shaker    New Brunswick   
       scientific  
Balance machine    Sartorius  
Cold centrifuge     Eppendorf  
FACS Calibur     Becton Dickinson 
Gel camera     Stratagene  
Heating blocks     Eppendorf  
Ice machines     Genheimer  
Laminar hoods     Heraeus  
Liquid nitrogen tank    Tec-lab  
Luminometer     Berthold  
Micro liter pipettes    Eppendorf  
Microcentrifuge    Eppendorf  
Microscope     Ziess 
pH meter     Ingold  
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Refrigerators (-20°C; -80°C)   Privileg and Bosch 
Ro shaking incubator    Eppendorf  
Spectrophotometer    Amersham Pharmacia  
Vortexer     Eppendorf  
Water bath     Eppendorf  
Western blot apparatus   Hoefer  
Real-Time RCR machine   ABI Prism 7000  
DL Ready
TM
 Luminometer   Berthold Technologies 
 
3.1.3.3 Kits  
 
Qiagen RNA isolation Kit   Qiagen 
Luciferase assay kit    Promega 
Site-directed mutagenesis kit    Strategene 
Qiagen Miniprep kit    Qiagen  
Qiagen Gel Extraction Kit   Qiagen  
Qiagen PCR purification kit   Qiagen  
cDNA synthesis kit    Invitrogen 
 
3.1.3.4 General materials and reagents for PCR, siRNA  and site directed 
mutagenesis 
 















Reverse 5’-agca tttgccatggacaagat3’ 
 
PCR reagents  
dNTPs       MBI Fermentas  
MgCl2       MBI Fermentas 
10x buffer       MBI Fermentas  
Taq polymerase      MBI Fermentas 
 
Transfection Reagent    Source 
Transfast for plasmid transfection  Promega 
Effectene for plasmid transfection  Qiagen 
Transmessenger for siRNA transfection Qiagen  
Lipofectamine for siRNA transfection  Invitrogen 
SilentFect for siRNA transfection  Bio-Rad 
 







#1- 5’ ccacaaaucugauaguauuu 3’,   
#2- 5’gaugagguauaucaaguuauu 3’ 
 
GSK3β - (SMARTpool siRNA) 
 




Expression vectors applied in this dissertation 
 
Mammalian expression vectors  Epitope tags 
wt-NFATc2 (pcDNA3.1)     HA  
NFATc2- ΔSP-2 (pcDNA3.1)    HA 
NFATc2- pSP-2 (pcDNA3.1)    HA 
NFATc2- K684R (pcDNA3.1)    HA 
NFATc2- K684/897R (pcDNA3.1)   HA 
NFATc2- ΔSP-2 – K684/897R (pcDNA3.1)  HA 
NFATc2 –1-460 (pcDNA3.1)    HA 
c.a. GSK3β (pcDNA3.1)     HA 
Sumo-1 (pcDNA3.1)     Flag 
Ubc-9 (pcDNA3.1)     Flag 
HDM2 (pcDNA3.1)     Flag 
pcDNA 3.1 (control vector)    HA 
GFP (control vector)     GFP 
 
Site-directed mutagenesis primers used in this work 
 
Mutation of Lysine 684 to Arginine 
For.  5’-cctgccatcaggacagagcccagc-3’ 
Rev.  5’- gctgggctctgtcctgatggcagggac-3’ 
 
Mutation of Lysine 897 to Arginine 
For. 5’ -ggagtgaccgtcagacaggaacag-3’ 
Rev. 5’-ctgttcctgtctgacggtcactcc-3’ 
 
Mutation of Ser215 and Ser219 to Alanine 
For. 5’-gctcattatgcccccagaaccgctccaataatg-3’ 
Rev. 5’-cgagtaatacgggggtcttggcgaggttattac-3' 
















C-terminus deletion of NFATc2 (NFATc2-1-460) 
 For.  5’- gag aac aag cct ctg ggg ctt tag atc ttc 3’  




List of antibodies used in various methods: Co-immunoprecipitation, 
immunofluroscence, and Western blots 
 
Antibodies    Dilutions  Source 
Mouse anti-mouse NFATc2  1:500   Santa Cruz 
Mouse anti-mouse HDM2  1:500   Santa Cruz 
Mouse anti-mouse Sumo-1  1:500   Santa Cruz 
Mouse anti-mouse p53  1:500   Santa Cruz 
Mouse anti-mouse CycninD1  1:1000   Cell Signaling 
Mouse anti-mouse CDK4  1:1,000  Cell Signaling 
Mouse anti-mouse CDK6  1:1,000  Cell Signaling 
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Mouse anti-mouse β-actin               1:10,000  Cell Signaling 
Rabbit anti-mouse Lamin A/C  1:1,000  Cell Signaling 
Rabbit anti-mouse GSK3β  1:1,000  Cell Signaling 
Rabbit anti-mouse phopho-  1:1,000  Cell Signaling 
-Glycogen synthase   
Mouse anti-mouse HA   1:1,000  Cell Signaling 
Mouse anti-mouse FLAG  1:1,000  Roche 
Mouse anti-mouse GFP  1:1,000  Roche 
Rabbit anti-mouse Ubiquitin  1:1,000  Biomol  
Rabbit anti-mouse ORC  1:1,000  Upstate     
 
3.1.4 Mediums and buffer solutions 
 
All chemicals of molecular biology research grade were procured from 
respective manufacturers and all solutions were prepared using pure 
distilled (Milli-Q grade) autoclaved water. Wherever necessary, solutions 
were sterile filtered or autoclaved.  
 
3.1.4.1 Cell biological 
 
PBS (Phosphate buffered saline) 
 8 g  NaCl 
 0.2 g  KCl 
1.44 g  Na2HPO4 
0.24 g  KH2PO4 
Dissolve in 800 ml dH2O, adjust pH to 7.4 with HCl 
Volume adjust to 1 L, autoclave and stored at RT 
 
Reagents      Source 
DMEM medium     Invitrogen 
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L-Glutamin (0.07%)     GIBCO 
Na-Pyruvat (1 mM)     GIBCO 
β-Mercaptoethanol (0.05 mM)   GIBCO 
MEM (non-essential amino acids) (1%)  GIBCO 
 Penicillin (100 U/ml)     GIBCO 
 Streptomycin (100 U/ml)    Fatol 





Composition of SDS-Polyacrylamide gels: Resolving Gel 
Component volumes (ml) per 10 ml gel mix for 8% to 12% 
H2O 3.3 - 4.6 ml 
30% acrylamide mix 2.7 ml - 4.0 ml 
1.5 M Tris (pH 8.8) 2.5 ml 
10% SDS 0.1 ml  
10% ammonium persulfate 0.1 ml  
TEMED 0.004 ml 
 
Stacking Gel 
Component volumes (ml) per 3 ml gel mix for 10% to 15% 
H2O 2.1 ml 
30% acrylamide mix 0.5 ml 
1.0 M Tris (pH 6.8) 0.38 ml 
10% SDS 0.03 ml 
10% ammonium persulfate 0.03 ml 
TEMED 0.003 ml 
 
Protein Loading Buffer (1X SDS gel loading buffer) 
50 mM Tris-Cl (pH 6.8) 
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100 mM Dithiothreitol 
2% SDS 
0.1% Bromophenol blue 
10% Glycerol 
 
Gel Running Buffer: (10X) 
144.13 g Glycine 
30.3 g Tris 
100 ml 10% SDS 
Volume adjusted to 1 L with dH2O 
 
Protein transfer buffer: (10X) 
145 g Glycine 
29 g Tris 
volume adjusted to 1 L with dH2O 
 
Blocking Solution 
5% (w/v) nonfat dried milk in TBS/0.1% Tween 
 
Agarose gel electrophoresis 
TBE buffer (1x): 
10.8 g  Tris 
5.5 g  Boric acid 
0.37 g  EDTA 
add  1 L H2O 
 
DNA Loading Buffer 
0.25% Bromophenol blue 
0.25% Xylene Cyanol FF 
30% Glycerol in water 
 
Materials & Methods 
26 
 
1% Agarose Gel:  
1.5 g Agarose 
150 ml 1x TBE buffer 
Boil and add 4 µl Ethidium bromide (10 mg/ml) 
 
Cell extract preparation 
Whole cell extract (WCE) buffer: 
5mM Tris HCL, pH7.4 
150 mM NaCl 
1 mM EDTA 
1% Triton X-100 
Protease inhibitor cocktail was added immediately before use 
.  
Cellular Fractionation Buffer 
For cytoplasmic protein: 
10 mM Hepes, pH 7.9 
10 mM  KCl 
0.1 mM EDTA 
0.1 mM EGTA 
0.1 M DTT 
 
For nuclear protein 
20 mM Hepes, pH 7.9 
0.4 M  NaCl 
1 mM EDTA 
1 mM EGTA 
0.1 M DTT 
Protease inhibitor cocktail was added immediately before use 
 
Cell lysis buffer for IP 
5 mM Tris HCL, pH7.4 
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150 mM NaCl 
1 mM EDTA 
1% Triton X-100 
(10X) wash buffer for IP 
0.5 M Tris HCL, pH 7.4, 1.5 M NaCl 
Protease inhibitor cocktail was added immediately before use 
3.1.4.3 Morphological 
 
Buffers for immunofluorescence  
Fixing solution  
4% formaldehyde in PBS 
Permeabilization solution  
0.2% Triton X-100 in PBS  
Blocking solution  
10% FCS in PBS (1:20) 
3.1.4.4 Molecular biological 
 
Restriction enzymes and buffers 
Reagent       Source 
Bam HI       BioLabs 
EcoRI       BioLabs 
Hind III-       BioLabs 
Not I       BioLabs 
Xho I       BioLabs 
Ligase, T4      BioLabs 
DNA polymerase, T4     BioLabs  
DNA polymerase, Klenow    BioLabs  
DNA Ladder, 1 kb     BioLabs  
DNA Ladder, 100 bp     BioLabs 
Phosphatase, calf intestinal (CIP)   BioLabs 
Phosphatase, shrimp alkaline (SAP)   Promega  
TAE buffer, 10X      Sigma  




3.2.1 Cell Culture 
 
MDA-MB-231, MDA-MB-435, MDA-MB-468, PaTu8988t, and IMIM-PC-1 
cell lines were purchased from ATCC (Manassas, Virginia, USA) and 
supplemented with 10% FCS in DMEM (Invitrogen, Karlsruhe, Germany). 
Cells were treated with 10-25 µM of zoledronic acid and harvested at 
indicated time points. All cell lines were found to be free of mycoplasma 
infection on repeated PCR screens. 
 
3.2.2 Plasmid constructs and transient transfection 
 
Flag-Sumo-1 and Ubc-9 expression constructs were provided by Dr. 
Guntrum Suske (Institute of Molecular and Tumor Biology, Marburg, 
Germany). Mouse NFATc2 and HDM2 constructs were generated in 
pcDNA3.1 (+) by sequential sub cloning of the HA-NFATc2 and HDM2 open 
reading frame into HindIII–XbaI and BamHI-XhoI. All mutations and 
deletions in NFATc2 were generated by site-directed mutagenesis and 
verified by DNA sequencing. The ΔSP2 (S 215/219/223 A) mutation was 
produced by mutating Serine 215, 219 and 223 to Alanine residues. The 
phospho mimicking (pSP2) mutation was produced by mutating existing 
mutant ΔSP-2 Alanine 215, 219, 223 to Aspartic acid. The K684/897R 
mutation was produced by mutating Lysine 684 and 897 to Arginine. For 
transient transfection MDA-MB-231, MDA-MB-435, cells were transfected 
by using the effectene transfection reagent (Qiagen) and PaTu8988 and 
IMIM-PC-1 cells were transfected with Transfast  (Promega) according to 
the manufacturer's instructions. 
 
 





Small interfering RNA (siRNA) was transfected using the Lipofectamine 
(Invitrogen) in MDA-MB-435 and MDA-MB-231 cells and 
TransmessengerTM reagent (Qiagen) in PaTu8988 and IMIM-PC-1 cells 
according to the manufacturer’s instructions. The specific siRNAs were 
purchased from Ambion Applied Biosystems (Austin, TX, USA) with the 
following sequences. siRNA against HDM2 and the SMARTpool siRNA 
against GSK3β was purchased from Dharmacon. As a negative control, the 
silencer negative control was purchased from Ambion. 
 
3.2.4 Preparation of whole protein extract from mammalian 
cells  
 
Cells were washed with ice cold PBS and then scraped in whole cell extract 
buffer. Then transferred them into 1.5 ml tubes. Kept on ice for 30 min to 1 
h. Cells were disrupted by two times freezing and thawing on dry ice or 
passing the cell suspension through 26 gauge needle 10 times and 
incubated for further 10 min. The cell suspension was centrifuged at 
15,000 rpm for 30 min at 4°C and supernatant was saved as whole cell 
extract in another 1.5 ml tube, which was stored for future use at -20°C. 
The protein concentration of the supernatant was determined by Bio-Rad 
protein assay.  
 
3.2.5 Preparation of nuclear and cytoplasmic protein extracts 
from mammalian cells  
 
Cells were washed and scraped in cold PBS. Transferred them into 1.5 ml 
tube and centrifuge at 1500 rpm for 5 min at 4°C to remove the 
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supernatant. The pellet was resuspended in 200 μl to 1 ml of extraction 
buffer A (100 μl per 1x10
7
 cells) and incubated for 20-30 min at 4°C or on 
ice. Extraction buffer A is a low salt buffer (indicates that DTT and PMSF 
were added to buffer A), which allowed the cells to swell. To destroy the 
swollen cells, the solution was passed 10 times through 1 ml syringe with 
26 gauge needle and centrifuged at 3,600 rpm for 20 min at 4°C. The 
supernatant contained cytosolic fraction and the pellet, which appeared 
transparent, containing nuclear fraction. The supernatant was transferred 
to a fresh 1.5 ml tube and kept on ice. The pellet was resuspended with 
200 μl extraction buffer C (leupeptin was added in addition to DTT and 
PMSF) by pipetting and vigorously mixing with force, followed by vortexing 
the nuclear extract vigorously for 30 min and incubate on ice for 30 min. 
Now the suspension was centrifuged at 15,000 rpm for 30 min at 4°C and 
supernatant containing nuclear proteins was frozen in –20°C. The protein 
concentration of the supernatant was determined by Bio-Rad protein 
assay. 
 
3.2.6 Protein determination  
 
The Bio-Rad protein assay is based on the observation that when 
Coomassie brilliant blue G-250 binds to the protein, the absorbency 
maximum shifts from 450 nm to 595 nm. Equal volumes of cell lysate 
containing 1-20 μg of protein was added to diluted dye reagent and mixed 
well (1:5 dilution of dye reagent concentrate in dH2O). After 5-10 min, the 
absorption at wavelength at 595 nm was measured versus reagent blank 
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3.2.7 SDS-polyacrylamide gel electrophoresis 
 
SDS-polyacrylamide gels were prepared in 8 cm x 10 cm x 1.5 mm mini gel 
format according to the standard Laemmli method. Separating or lower gel 
mix was prepared according to the volume required, poured in the gel 
apparatus, overlaid gently with 0.1% SDS and before the separating gel 
polymerized, immediately poured the stacking gel, the comb was inserted 
and allowed to polymerize at RT for 1 h to 2 h. Requisite concentrations of 
protein samples were mixed with 4x Laemmli buffer and denatured by 
heating at 95°C for 5 min, loaded in the wells, (one well was loaded with 
protein marker) of polymerized gel and electrophoresed at constant 
current initially at 120 V and when the marker start separating current 
increased up to 160 V per gel in 1X SDS-PAGE running buffer. 
 
3.2.8 Western blotting 
 
SDS-PAGE gel was electrotransferred onto nitrocellulose membrane at 300- 
400 mA for 90 min at 4°C. The air dried membrane was incubated in a 
blocking solution (5% fat free milk in 1X TBS-Tween) for 1 h at RT. 
Membrane was directly incubated in primary antibodies against cyclinD1, 
CDK4, CDK6, GSK3β, HA, Lamin a/c, HDM2, p53, NFATc2, Ubiquitin and β-
actin antibodies over night at 4°C. After incubation, the membrane was 
washed in 1X TBS-Tween for 3 X 10 min each. Now membrane was 
incubated in secondary antibodies conjugated with peroxidase against 
mouse or rabbit antibody for 1-2 h at room temperature and washed in 1 X 
TBS-Tween for 3 X 10 min each. Proteins were visualized and developed 
with ECL developing solution according to the manufacturer's instructions. 
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3.2.9 Proliferation Assay and Cell Cycle Analysis 
 
MDA-MB-231, MDA-MB-435, PaTu8988t, IMIM-PC-1 cells were seeded in 
12-well plates and cultured in medium containing 10% FCS. Cells were kept 
in the presence of 10 or 25 µM zoledronic acid for indicated time periods. 
[
3
H] thymidine (0.5mCi/well) was added during the last 6 h of incubation. 
Incorporated [
3
H] thymidine was quantified as described previously. Cell 
cycle analysis was performed by flow cytometry. Cells were treated with 10 
µM zoledronic acid for 72 h, trypsinized, washed with PBS and fixed in 70% 
ethanol. After washing with PBS, cells were incubated with 20 µg/ml 
RNase, DNase-free water with 50µg/ml propidium iodide for 3 h at RT 
under light protection. The DNA content of 10
6
 cells was analyzed on a 
Becton Dickinson FACS Calibur flow cytometer (San Jose, CA, USA). The 
fractions of cells in the G0/G1, S and G2/M phases were calculated using 
Cell Quest software from Becton Dickinson (Topsham, ME, USA). 
 
3.2.10 In vivo Tumor Xenograft Studies 
 
6-8 weeks old female athymic nu/nu mice were obtained from Harlan 
Laboratories (San Diego, CA, USA) and housed in the animal care facility of 
University hospital of Marburg, under pathogen-free conditions. IMIM-PC-1 
cells were detached from the culture dishes by trypsinization and then 
collected, washed, and resuspended in DMEM. To establish IMIM-PC-1 
tumor xenografts, mice were injected s.c. with 1 × 10
6
 IMIM-PC-1  cells 
mixed with 50 μL DMEM + 50 μL Matrigel (BD Biosciences) in the right and 
left flanks of each mouse. One week after injection, tumors were size 
matched and mice were randomized into two treatment groups: animals in 
group I (control) received 10% DMSO; and group II received 1 mg/kg 
zoledronic acid, i.p., 3 days per week. Once xenografts started growing, 
their sizes were measured with caliper twice in a week. Tumor volume was 
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calculated using the formula for volume of an ellipsoid: 4/3π × (L / 2) × (W / 
2) × (H / 2), where L is the length, W is the width, and H is the height. 
Protocols for animal handling and experimentation were approved by the 
animal research facility of the University hospital of Marburg. 
 
3.2.11 Real-Time PCR 
 
RNA was extracted using the RNeasy Mini Kit (Qiagen) and first-strand 
cDNA was synthesized from 1 µg total RNA using random primers 
(Superscript first-strand synthesis kit). The RT-PCR was performed using a 
7500 Fast-Real-Time-PCR-System from Applied Biosystems. Specific primer 




Cells were lysed in either RIPA buffer (50 mM Tris HCL, pH 7.5, 150 mM 
NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 0.2 mM PMSF, 2 mM 
orthovanadate and 20 mM N-ethylmaleimide) supplemented with protease 
inhibitor cocktail or lysis buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1 
mM EDTA, 1% Triton X-100, and 20 mM N-ethylmaleimide) supplemented 
with protease inhibitor cocktail. For immunoprecipitaion, lysates were 
incubated overnight at 4°C with the relevant antibodies (3 μg anti-NFATc2, 
3 μg anti-HDM2 or 3 μg of anti-HA; anti-Flag) followed by a 2 h incubation 
with protein A or G agarose beads at 4°C (Upstate, USA). The beads were 
then washed three times with washing buffer (50 mM Tris HCl, pH 7.4, 150 
mM NaCl) or PBS, supplemented with protease inhibitor cocktail. Than 
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3.2.13 Immunofluorescence  
 
Cells were grown on chambered cover slips and they were washed three 
times with PBS and then fixed in 4% paraformaldehyde for 10 min at RT. 
After fixation, cells were washed two times in PBS and permeabilized in 
PBS containing 0.2% Triton X-100 for 20 min. Cells were blocked in PBS 
containing 10% FCS at RT for 1 h and incubated with anti-HA in blocking 
solution. Cells were washed three times with PBS and incubated for 1 h at 
RT Cy3-conjugated goat-anti-mouse secondary antibody (Dianova, Jackson 
ImmunoResearch Laboratories, USA) in blocking solution and nuclei 
counterstained with DAPI (containing 1.5 µg/ml). Cover slips were 
mounted on glass slides and preparations were observed with a 
fluorescence microscope (Carl Zeiss, Göttingen, Germany). 
 
3.2.14 Immunohistochemistry with ABC-peroxidase method 
 
Paraffin embedded sections of human pancreatic and breast cancer tissues 
of 2-3 µm were deparaffinized with xylene (3 x 5 min) followed by 
rehydration in a series of ethanol (2 x 99%, 96%, 80%, 70%, 50% ETOH, 1.5 
min each step). For antigen retrieval and improved accessibility of 
epitopes, rehydrated sections were subjected to 0.01% trypsin digestion 
for 10 min at 37°C and additional irradiation for 3 x 5 min in a microwave 
oven (850 W, in citrate buffer, pH 6) with subsequent cooling 1 h at RT. 
Blocking of endogenous peroxidase was done by incubating the sections 
for 5 min with 3% H2O2 (Merck, Darmstadt, Germany) in a moist chamber 
at RT. Non-specific protein binding sites and endogenous biotinylated 
proteins in these sections were blocked for 2 h with 10% FCS in PBS pH 7.4) 
containing avidin (Avidin/Biotin blocking kit, Vector, Burlingame, CA). 
Washing steps were performed between all following steps with PBS for 5 
min. After washing, sections were incubated overnight with primary 
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antibodies in 10% FCS at 4°C, including free biotin to saturate the bound 
avidin (Avidin/Biotin blocking kit. For detection of antigen-antibody 
complexes the sections were incubated with a biotinylated secondary 
antibody for 1 h at RT. The bound secondary antibody was detected with 
peroxidase-coupled extravidin system and visualized by histochemical 
staining. This reaction was stopped with H2O and the sections were 
counterstained with hematoxylin for 10 min. Negative controls were 
incubated in parallel without primary antibody. These sections were 
analyzed by a photo microscope (Zeiss). 
3.2.15 Ubiquitination Assays 
 
Cells were treated with ZOL (10 µM) for 32 h followed by MG132 (10 µM) 
for at least 12 h. After that cells were lysed and subjected to 
immunoprecipitation. Anti-NFATc2 immunoprecipitates or anti-HA or anti-
HDM2 immunoprecipitates were immunoblotted against anti-ubiquitin 
(BioMol). 
 
3.2.16 Luciferase Reporter Assays 
 
For luciferase reporter gene assays, 10
6 
cells were seeded onto 12-well 
tissue culture dishes and transfected after 24 h with the above indicated 
constructs. Cells were treated for 72 h in the presence of zoledronic acid 
(10 µM) then luciferase assays were performed with a luminometer and 
the Dual-Luciferase
®
-Reporter Assay System (Promega). Firefly luciferase 
values were normalized to Renilla luciferase activity and were either 
expressed as relative luciferase activity (RLA) or as mean ‘fold induction’ 
with respect to empty vector control. Mean values are displayed +/- 
standard deviations. 
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3.2.17 Statistical analysis 
 
Each experiment was reproduced at least three times. Values were 
expressed as the mean ± SD of triplicate measurements unless otherwise 
stated. Student’s paired t-test was used to analyze differences between the 
sample of interest and its control. Time courses and dose responses were 
compared by multiple measurements ANOVA and corrected by Student-
Newman–Keul’s test for differences between groups. A p value of less than 






4.1 ZOLEDRONIC ACID INHIBITS CANCER CELL 
PROLIFERATION BY INDUCING G1/S PHASE ARREST 
To investigate the effect of zoledronic acid on tumor cell proliferation, we 
performed proliferation assays by measuring 
3
H-thymidine incorporation in 
MDA-MB-435, MDA-MB-231, IMIM-PC-1, PaTu8988t and MDA-MB-468 
cells. Treatment with zoledronic acid led to a dramatic reduction in 
proliferation rates of MDA-MB-435, MDA-MB-231, IMIM-PC-1 and 8988t 
cells respectively (Fig. 5A). In contrast, cell growth remained unaffected in 
MDA-MB-468 cells (Fig. 5C). Reduction of cell proliferation occurred in a 
time-dependent manner and became significant after 48 h in zoledronic 
acid responsive cancer cell lines. Maximal growth suppression was reached 




Fig. 5. Zoledronic acid inhibits cancer cell proliferation. (A) MDA-MB-435, MDA-MB-231, 
IMIM-PC-1, 8998t cells were treated with zoledronic acid (10 µM) in serum condition. 72 h 
after treatment, cells were subjected to a proliferation assay by incorporation of 
3
H 
thymidine. (B) MDA-MB-435 cells were treated with zoledronic acid (10 µM) with the 
indicated time points (C) Zoledronic acid non-responsive MDA-MB-468 cells were treated 
with the zoledronic acid (10 µM) in serum condition. 72 h after treatment, cells were 
subjected to a proliferation assay by incorporation of 
3
H thymidine. Data are 
representative of triplicate experiments and are displayed as bars ± SD. 
  
To determine whether zoledronic acid mediates growth inhibition, which 
could be due to cell cycle inhibition, therefore we assessed the effect of 
zoledronic acid on cell cycle regulation by using flow cytometry analysis. 
Zoledronic acid treated and untreated cancer cells revealed that this effect 
was most likely due to induction of cell cycle arrest, as evidenced by the 
shift of cells in G1 phase and synchronization of cells in phase in 
corresponding MDA-MB-435 and MDA-MB-231 cells (Fig. 6). Time course 
analysis after treatment with 10 µM zoledronic acid in MDA-MB-435 and 
MDA-MB-231 cells revealed decreased expression of cyclin D1 and its 
corresponding kinases CDK4 and CDK6 over time, reflecting cell cycle 
inhibition. Maximal inhibition was seen after 72 h consistently in both cell 
lines (Fig. 7). Thus, zoledronic acid suppresses proliferation of cancer cells 






Fig. 6. Zoledronic acid induces G1/S phase arrest in cancer cells. MDA-MB-435 and MDA-
MB-231 cells were treated with zoledronic acid (10 µM) in serum containing medium. 
After 72 h of treatment with zoledronic acid, flow cytometry analysis was performed after 
propidium iodide (PI) staining. Cell cycle stages are illustrated in different colors: G2 




Fig.7. Zoledronic acid down regulates G1/S phase regulatory proteins in a time 
dependent fashion. Western blot analysis to examine the effect of zoledronic acid on the 
expression of cell cycle regulatory genes in growth promoted cell lines. Cells were treated 
with 10 µM zoledronic acid in indicated time points. Total cell lysates were then analyzed 
for expression of D-type cyclins and their kinase partners (CDKs). Protein loading was 





4.2 EFFECTS OF ZOLEDRONIC ACID, ON THE 
GROWTH OF IMIM-PC-1 TUMORS IN ATHYMIC   
NUDE MICE 
To determine the in vivo relevance of our in vitro findings, we selected 
athymic nude mice and injected pancreatic cancer cells (IMIM-PC-1) 
subcutaneously. Mice were treated with a sterile
 
i.p. injection of 10% 
DMSO in 0.9% NaCl. To determine
 
the effect of zoledronic acid treatment 
on the growth of tumors in this xenograft mouse model, we compared 
treatment with zoledronic acid
 
1 mg/kg intraperitoneal (i.p). 3 days per 
week, (n = 7) with a control group (n = 7). We observed that zoledronic acid 
significantly reduces the growth of tumors compared to the control group 
(p< 0.05; Fig. 8). 
 
 
Fig. 8. Antitumor effects of zoledronic acid inhibition in vivo. IMIM-PC-1 tumor 
xenografts mice were injected subcutaneously (s.c.). with 1 × 10
6




with 50 μL DMEM + 50 μL matrigel in the right and left flanks of each mouse. One week 
after injection, tumors were size matched and mice were randomized into two treatment 
groups: animals in group I (control) received 10% DMSO in 0.9% NaCl; and group II 
received 1 mg/kg zoledronic acid, i.p., 3 days per week. Photographs of representative 
mice with tumors from each group (upper panel). Photographs of excised tumors from 
each group (lower-left panel). Average tumor volume of DMSO control and zoledronic acid 
treated mice plotted over days after tumor cell inoculation (lower-right panel). Once 
tumors started growing, their sizes were measured with calipers in three dimensions two 
times weekly. Tumor volume was calculated using the formula for volume of an ellipsoid: 
4/3π × (L / 2) × (W / 2) × (H / 2), where L is the length, W is the width, and H is the height 
points mean of seven animals; bars, SD.; P < 0.05. Results were analyzed using student’s 
paired t- test, and p< 0.05 was considered significant.  
 
4.3 NFATc2 PROMOTES G1/S-PHASE TRANSITION IN 
CANCER CELLS 
NFATc2 exerts strong oncogenic properties through its ability to promote 
cancer cell growth and migration. We observed the localization and 
expression of NFATc2 in a series of breast and pancreatic cancer tissues 
(Fig. 9) and also in all investigated cancer cell lines (Fig. 10). 
 
Fig. 9. NFATc2 expression in human breast and pancreatic cancer tissues. 
Immunohistochemical analysis of NFATc2 expression and localization in human breast 





To investigate the role of NFATc2 in cancer cell proliferation, we first used 
MDA-MB-231 and MDA-MB-435 cells and performed proliferation assays 
by measuring 
3
H-thymidine incorporation in the presence or absence of 
NFATc2. For this purpose, we transiently knocked down NFATc2 expression 
in MDA-MB-435 and MDA-MB-231 cells by using RNAi technology, 
illustrating successful silencing of NFATc2 in MDA-MB-231 cells upon 
transfection of siRNA #2 and #3 (Fig. 10). 
 
Fig. 10. Transient knock down of NFATc2 by using siRNA. MDA-MB-231 cells were 
transiently transfected with three different oligonucleotide sequences of NFATc2 or 
control siRNA. After 24 h of transfection cell were then analyzed for expression of NFATc2 
or β-actin antibody. 
 
We then used oligonucleotide sequence #3 or control siRNA for further 
analysis to examine the effects of NFATc2 knockdown on cell growth in 
MDA-MB-435 and MDA-MB-231 cells. In both conditions, NFATc2 
expression was dramatically reduced compared to control cells (Fig. 11, 
upper panel). We next assessed the effect of NFATc2 silencing on cell 
proliferation using 
3
H thymidine incorporation. In both cell lines, silencing 
of NFATc2 resulted in a potent inhibition of cell proliferation compared to 
cell transfected with control siRNA, (Fig. 11, lower panel), and this is 





Fig. 11. NFATc2 is required for cancer cell proliferation. MDA-MB-231 and MDA-MB-435 
cells were transiently transfected with NFATc2 siRNA (NFATc2 siRNA #3) or control siRNA 
(upper panel). After transfection, cells were subjected to a proliferation assay by 
incorporation of 
3
H thymidine (lower panel). Data are representative of triplicate 
experiments and are displayed as bars ± SD. In the upper panel, NFATc2 expression levels 
were determined by immunoblotting with NFATc2 and β-actin as loading control.  
 
In addition, expression analysis revealed that analogy to the effects of 
zoledronic acid treatment, in the NFATc2 knock-down cells showed a cell 
cycle arrest caused by reduced levels of cyclin D1 and its partner kinase 
CDK6 (Fig. 12). Thus, NFATc2 activity is required for the proliferative 
capacity of cancer cells, and reduction of NFATc2 activity results in near 
complete loss of the G1/S phase regulatory cyclins and their kinases, which 






Fig. 12. NFATc2 targets G1/S phase genes to induce tumor cell proliferation. MDA-MB-
435 cells were transiently transfected with NFATc2 siRNA (NFATc2 siRNA #3) or control 
siRNA. After transfection, lysates were immunoblotted with anti-NFATc2, D-type cyclins 
and their kinase partners (CDKs). Protein loading was controlled by using β-actin antibody. 
 
4.4 ZOLEDRONIC ACID SUPPRESSES NFATc2 
ACTIVITY THROUGH ENHANCED PROTEASOMAL 
DEGRADATION 
 
We next investigated the mechanism by which zoledronic acid could block 
cell proliferation. We sought to implicate zoledronic acid in the modulation 
of growth control through NFATc2 in cancer cells. To test this hypothesis, 
we first evaluated NFATc2 transcriptional activity by reporter gene assays 
using a NFAT responsive promoter reporter construct (cisNFAT) bearing 
GGAAA NFAT concensus binding sites obtained from the IL-2 promoter. 
Upon introduction of NFATc2 caused a six-fold induction of the cis-NFAT 
reporter construct. However, treatment of cells with zoledronic acid leads 




suggesting that zoledronic acid treatment antagonizes the transcription 
activity of NFATc2 in cancer cells (Fig. 13). 
 
 
Fig. 13. Zoledronic acid blunts NFATc2 transactivation. MDA-MB-231 cells were 
transiently transfected with the cis-NFAT luciferase reporter plasmid and the indicated 
NFATc2 plasmids, or empty vector control. After transfection, cells were treated with 
zoledronic acid (10 µM) for 48 h, then lysed and luciferase assays were performed. Data 
are representative of triplicate experiments and are displayed as bars ± SD. 
 
In fact, western blot analysis revealed a significant reduction of 
endogenous NFATc2 expression levels in MDA-MB-435, MDA-MB-231 and 
IMIM-PC-1 cells after 72 h of zoledronic acid treatment (Fig. 14) 
Interestingly, the level of NFATc2 remained unaffected in MDA-MB-468 
cells (Fig. 14). Time dependent experiments showed that NFATc2 protein 
expression in MDA-MB-435 cells was abolished after 48 h (Fig. 15). 
 
Fig. 14. Zoledronic acid reduces NFATc2 protein expression. Expression level of NFATc2 in 




zoledronic acid (10 µM), 72 h after treatment protein levels of NFATc2 in the cells were 
determined by immunoblotting. 
 
Fig. 15. Zoledronic acid reduces NFATc2 protein expression in a time dependent manner. 
In MDA-MB-435 cells, time course experiment showing NFATc2 protein expression in 
indicated time points after zoledronic acid treatment. 
 
Furthermore, inhibition of NFATc2 protein expression in MDA-MB-435 and 
MDA-MB-231 did not result from disrupted mRNA expression (Fig. 16), but 
was the consequence of increased protein turnover and degradation. 
While zoledronic acid did not affect the level of NFATc2 mRNA expression, 
it dramatically lowered NFATc2 protein levels in all responsive cell lines. 
 
 
Fig. 16. Zoledronic acid does not alter NFATc2 mRNA expression. MDA-MB-231 and 
MDA-MB-435 cells were treated with zoledronic acid (10 µM) for indicated time points. 
Bars are showing NFATc2 mRNA expression was measured by real-time PCR using NFATc2 
and XS-13 oligonucleotides. Data are representative of triplicate experiments and are 





Moreover, zoledronic acid induced loss of NFATc2 expression was 
completely rescued by pre-treatment of cells with MG-132, a cell-
permeable and reversible proteasome inhibitor that allows ubiquitination 
but reduces the subsequent degradation of ubiquitin-conjugated proteins 
by the 26S proteasome complex (Fig. 17). Indeed, immunoprecipitation 
from zoledronic acid treated cells showed a strong ubiquitination signal 
upon administration of zoledronic acid with a characteristic ladder, 
indicative for polyubiquitination. Noteworthy, the ubiquitination signal was 
weakly detectable in cells without zoledronic acid, indicating that a basal 
turnover of NFATc2 also exists in the absence of zoledronic acid. 
Accordingly, we found increased expression levels of NFATc2 upon 
pretreatment of cells with MG-132 (Fig. 18). Taken together, these results 
show that zoledronic acid targets the mitogenic transcription factor 
NFATc2 for ubiquitination and proteasomal degradation in growth 
inhibited cancer cells. 
 
 
Fig. 17. Zoledronic acid promotes NFATc2 proteasomal degradation. MDA-MB-435 cells 
were treated with zoledronic acid (10 µM) for 32 h in complete media, then treated with 
MG132 (10 μM) or DMSO control for at least 12 h. After 48 h cells were lysed and total cell 
lysates were immunoblotted with NFATc2 antibodies. Protein loading was controlled by 





Fig. 18. Zoledronic acid induces NFATc2 ubiquitination and proteasomal degradation. 
MDA-MB-435 cells were treated with zoledronic acid (10 µM) for 32 h in complete media, 
then treated with MG132 (10 μM) or DMSO control for at least 12 h. After 48 h cells were 
lysed and NFATc2 immunoprecipitates were immunoblotted with ubiquitin and NFATc2 
antibodies. 
 
4.5 HDM2 IS REQUIRED FOR ZOLEDRONIC ACID 
MEDIATED PROTEASOMAL DEGRADATION OF 
NFATc2   
 
Polyubiquitination is mediated by and required for E3-ligase induced 
substrate degradation. HDM2, the human homolog of the E3-ligase MDM2 
(murine double minute 2), is a nucleoplasmic RING-finger protein 
interacting with several tumor suppressor proteins including p53, 
retinoblastoma protein, p14ARF and promyelocytic leukemia protein 
(PML). HDM2 controls the levels of p53 by acting as an E3 ubiquitin ligase 
initiating p53 proteasomal degradation. It has recently been shown that 
HDM2 is activated by the Pi3K-AKT pathway in breast cancer cells and this 
mechanism has been associated with inhibition of NFAT mediated cancer 
cell migration (Yoeli-Lerner et al., 2005). We therefore, tested whether 
HDM2 is involved in zoledronic acid mediated degradation of NFATc2. First, 




cellular HDM2 and loss of NFATc2 in MDA-MB-435 and MDA-MB-231 cells 
(Fig. 19). We also found that zoledronic acid induced HDM2 expression and 
NFATc2 degradation in a dose dependent manner (Fig. 20). In addition, 
overexpression of HDM2 reduced endogenous NFATc2 protein levels in a 
dose dependent manner respectively (Fig. 21).     
 
 
Fig. 19. Zoledronic acid induces E3-ligase HDM2 protein expression. MDA-MB-435 and 
MDA-MB-231 cells were treated with zoledronic acid (10 µM). After 72 h of treatment 
total cell lysates were subjected to analyze the expression of NFATc2 and HDM2. Protein 
loading was controlled by using β-actin antibody. 
 
Fig. 20. Zoledronic acid induces E3-ligase HDM2 protein expression in a dose dependent 
manner. MDA-MB-435 and MDA-MB-231 cells were treated with zoledronic acid (10 or 25 
µM). 72 h after treatment, total cell lysates were subjected to analyze the expression of 





Fig. 21. Overexpression of HDM2 in MDA-MB-435 cells. MDA-MB-435 cells were 
transfected with different doses of HDM2. After 36 h of transfection, total cell extracts 
were immunoblotted with anti-NFATc2, anti-HDM2 and anti-p53. 
 
Second, immunoprecipitation assays demonstrated physical interaction 
between HDM2 and NFATc2 in both cell lines. Thus, it appeared likely that 
HDM2 can promote NFATc2 degradation in response to zoledronic acid. 
We therefore assayed the ability of HDM2 to interact with and to induce 
ubiquitination and degradation of NFATc2. Co-immunoprecipitation studies 
showed that HDM2 readily interacts with endogenous NFATc2 in untreated 
cells which explains the low level of ubiquitination and degradation of 
NFATc2 in unstimulated cells (Fig. 22). 
 
Fig. 22. E3 ligase HDM2 physically interacts with NFATc2. Total cell lysates from MDA-
MB-231 cells were immunoprecipitated using anti-NFATc2 or anti-HDM2 and control (IgG) 





Moreover, knockdown of HDM2 by RNA interference stabilized 
endogenous NFATc2 protein level and, in addition, prevented NFATc2 
degradation and its downstream targets cyclin D1 and its kinases in 
response to zoledronic acid (Fig. 23). Surprisingly, silencing of HDM2 
rescued cell proliferation in response to zoledronic acid (Fig. 24).  
 
 
Fig. 23. E3-ligase HDM2 promotes NFATc2 degradation in response to zoledronic acid. 
MDA-MB-231 cells were transfected with HDM2 siRNA (HDM2 siRNA #1 and #2), or 
control siRNA. After transfection, cells were treated with zoledronic acid (10 µM) for 48 h 
in serum media then lysates were immunoblotted with NFATc2, HDM2, cyclin D1 and their 





Fig. 24. Zoledronic acid inhibits cell proliferation through HDM2. MDA-MB-231 cells were 
transfected with HDM2 siRNA (HDM2 siRNA sequences #1 and #2), or control siRNA. 48 h 
after transfection, cells were subjected to a proliferation assay by incorporation of 
3
H 
thymidine. Data are representative of triplicate experiments and are displayed as bars ± 
SD.  
In addition, HDM2 was also responsible for mediating NFATc2 
ubiquitination upon zoledronic acid, as NFATc2 ubiquitination was not 
detectable in HDM2 knockdown cells. Together, these results indicate that 





Fig. 25. E3-ligase HDM2 is required for ubiquitination followed proteasomal degradation 
of NFATc2 in response to zoledronic acid. MDA-MB-435 cells were transfected with 
HDM2 siRNA or control siRNA. After transfection, cells were treated with zoledronic acid 
(10 µM). After 48 h cells were lysed and NFATc2 immunoprecipitates were immunoblotted 
with ubiquitin and NFATc2 antibodies. Total lysates were immunoblotted to reveal 
expression of HDM2. 
 
4.6 ZOLEDRONIC ACID INHIBITS GSK3β KINASE 
ACTIVITY AND INDUCES NUCLEAR ACCUMULATION 
OF HDM2 TO DEGRADE NFATc2 
 
Nuclear translocation and accumulation of NFATc2 are prerequisites for 
transcriptional activity. We therefore evaluated whether zoledronic acid 
degrades NFATc2 in the nucleus or in the cytosol. After treatment with 
zoledronic acid (10 µM), nuclear and cytosolic extracts were 
immunoblotted for NFATc2 (Fig. 26). In untreated cells, NFATc2 was 
detected at equivalent levels in the cytosol (inactive) and nucleus (active). 




a striking reduction of NFATc2 protein in the nucleus following treatment 
with zoledronic acid. In the rescue experiment, nuclear NFATc2 levels were 
measurably increased in cells treated with MG-132 in combination with 
zoledronic acid (Fig. 27). 
 
Fig. 26. Zoledronic acid targets NFATc2 in the nucleus. MDA-MB-435 cell were treated 
with zoledronic acid (10 µM) for 72 h. Nuclear and cytoplasmic fractions were then 
analysed by immunoblotting with the indicated antibodies. Protein loading was controlled 
using lamin a/c and β-actin antibodies. 
 
Fig. 27. Zoledronic acid induces NFATc2 degradation exclusively in the nucleus. Cells 
were treated with zoledronic acid (10 µM) for 32 h, then treated with MG132 (10 µM) or 
DMSO control, after 48 h cells were lysed and nuclear extracts were immunoblotted, 
NFATc2 antibodies were used. Protein loading was controlled using lamin a/c. 
 
In the next experiment, subcellular fractionation further showed an inverse 
correlation between the level of nuclear HDM2 and NFATc2 upon 
zoledronic acid treatment. In fact, HDM2 strongly accumulated in the 
nuclei of zoledronic acid treated cells, in which NFATc2 expression 
declined. Moreover, HDM2 strongly accumulated in the nucleus upon 




reduction of NFATc2 mainly occurs in the nucleus, while cytoplasmic 
NFATc2 remained unaffected by zoledronic acid (Fig. 28). 
 
Fig. 28. Zoledronic acid induces HDM2 protein expression exclusively in the nucleus that 
leads to NFATc2 proteosomal degradation. MDA-MB-435 cells were treated with 
zoledronic acid (10 µM) for 72 h, nuclear and cytosolic extract were immunoblotted with 
NFATc2, HDM2 and lamin a/c as a nuclear loading control. 
 
Several protein kinases that can phosphorylate NFAT and control its 
nuclear-cytoplasmic shuttling are known. We were especially interested in 
GSK3β, which is a substrate of Akt. Recently, It has been shown that Akt-
signaling through inhibition of GSK3β induces NFATc2 turnover and blocks 
breast cancer cell migration (Yoeli-Lerner et al., 2009). Prompted by these 
recent findings, we investigated the role of GSK3β and NFATc2 stabilization 
pathways under the influence of zoledronic acid and sought to determine 
the expression pattern of GSK3β in human pancreatic cancer tissue. Using 
immunohistochemical staining, we found high levels of GSK3β and NFATc2 









Fig. 29. NFATc2 and GSK3β expression in human pancreatic cancer tissue. 
Immunohistochemical analysis of NFATc2 (left panel) and GSK3β (right panel) expression 
and localization in human pancreatic cancer tissues. Scale bars, 250 µm and 100 µm. 
 
However, treatment with zoledronic acid blunts GSK3β activity by its 
phosphorylation at Ser-9 residues, results in blocked activity of its 
substrate glycogen-synthase kinase. These findings were observed in all 
tested cancer cell lines (Fig. 32). After dose dependent treatment with 
zoledronic acid, nuclear fractionation revealed that zoledronic acid induces 
GSK3β phosphorylation which leads to nuclear NFAT inactivation by 






Fig. 30. Zoledronic acid blunts GSK-3β activity by Ser-9 phosphorylation. PaTu8988t cells 




immunoblotted with NFATc2, pGSK3β and GSK3β antibodies. Phosphorylated and 
unphophorylated forms of NFATc2 are indicated by arrows. 
 
Fig. 31. Zoledronic acid inactivates GSK-3β exclusively in the nucleus. IMIM-PC-1 cells 
were treated with zoledronic acid (10 µM) for 72 h, nuclear and cytosolic extracts were 
immunoblotted with NFATc2, pGSK3β and GSK3β antibodies. 
 
Fig. 32. Loss of GSK-3β activity reduces NFATc2 expression. MDA-MB-435 cells were 
treated with zoledronic acid (10 µM), after 72 h nuclear lysates were analyzed for 
expression of NFATc2, pGSK3β, p-glycogen synthase. Protein loading was controlled using 
β-actin antibodies. 
  
These findings prompted us to investigate the role of GSK3β in NFATc2 
stabilization. Therefore, we demonstrated that knockdown of GSK3β by 
siRNA in MDA-MB-435 cells resulted in a decreased level of NFATc2, as 





Fig. 33. GSK3β requires for NFATc2 stability. 8988t cells were transfected with GSK3β 
siRNA or control siRNA. After 24 h of transfection, lysates were immunoblotted with 
indicated antibodies. Protein loading was controlled by using β-actin antibodies. 
 
To provide a causal and direct demonstration of the effect of GSK3β on 
NFATc2 stability, we used the GSK3β.S9A mutant which is Akt/PKB 
unresponsive. We transfected constitutively active (c.a.) GSK3β or vector 
control. Phophorylation of GSK3β at one key residue on serine 9 is required 
for its inactivation. Mutation of serine 9 to Alanine renders the GSK3β 
constitutively active. Upon zoledronic acid treatment, NFATc2 was totally 
rescued compared to control cells (Fig. 34). Taken together, these results 
show that phosphorylation of GSK3β at Ser9 by zoledronic acid, which 
inhibits GSK3β activity, is required for NFATc2 stability in the nucleus.  





Fig. 34. Active GSK3β protects NFATc2 from zoledronic acid mediated proteasomal 
degradation. MDA-MB-435 cells were transfected with either vector control or 
constitutively active GSK3β (Ser 9 to Ala). After 18 h of transfection, cells were treated 
with zoledronic acid (10 µM) for 72 h in serum containing media. Total lysates were 
immunoblotted with NFATc2, HA-GSK3β or pGSK3β antibodies. Protein loading was 
controlled using β-actin antibodies. 
 
4.7 GSK3β PHOSPHORYLATION AT THREE KEY 
RESIDUES ELEVATES CELLULAR NFATc2 LEVELS 
AND RESCUES IT FROM ZOLEDRONIC ACID 
MEDIATED PROTEASOMAL DEGRADATION 
 
Finally, we investigated the mechanism by which zoledronic acid and 
GSK3β signaling attenuates NFATc2 degradation. Consistent with the 
results shown in Fig. 33, siRNA mediated silencing of GSK3β in MDA-MB-
435 cells results in a marked reduction of NFATc2 protein. In contrast, using 
c.a. GSK3β mutants, rescued NFATc2 from being degraded under 





 Sequence analysis revealed that three key serine residues (Ser 213, Ser 
217 and Ser 221)  located within the N-terminal  SP2 motif of NFATc2 and 
they are conserved in both human and mice (Kehlenbach et al., 2000; Beals 
et al., 1997) (Fig. 35). GSK3β is known to mediate NFATc2 phosphorylation 
at these sites (Beals et al., 1997). To further support the evidence that 
GSK3β mediated phosphorylation of NFATc2 alters its stability towards 
zoledronic acid mediated degradation, we investigated the effects of 
different doses of HDM2-mediated degradation of wild type (wt) NFATc2, 
NFATc2-pSP2, a phosphorylation-mimic mutant in which all three serine 
residues were substituted for Aspartic acid, and NFATc2-∆SP2, a non-
phosphorylation-mimic mutant in which all three serine residues were 
substituted for Alanine with two NFATc2 mutants. Interestingly, we could 
show that high doses of HDM2 declined protein level of wild type NFATc2 
and notably, even more efficiently to NFATc2-∆SP2 (Fig. 36B). However, 
high dose of HDM2 did not affect NFATc2-pSP2 on protein level. Together 
with the data shown in Fig. 36B, these results suggest that phosphorylation 
of NFATc2 at three key serine residues by GSk3β regulates NFATc2 protein 
stability as well as it keeps it away from HDM2 mediated degradation. 
 
 
Fig. 35. GSK3β phosphorylation sites are conserved among human and mouse NFATc2. 
The putative GSK3β consensus sequences for possible phosphorylation sites on NFATc2 














Fig. 36. Phosphorylation of S215/217/221 is crucial for NFATc2 stability. (A) Schematic 
representation of wild-type (WT) HA-NFATc2, NFATc2-∆SP2 and NFATc2-pSP2 mutants, 
including the position of the putative NFATc2 phosphorylation (Ser 215, 217 and 219) 
sites. The described mutations in all three Ser are indicated in different colors. (B) MDA-
MB-435 cells were co-transfected with the indicated wild-type (WT) HA-NFATc2 or 
mutants NFATc2-pSP2 and NFATc2-∆SP2, either alone or in combination with different 
doses of HDM2, as indicated. Cell extracts were immunoblotted with either anti-HA or 
anti-HDM2. 
 
To analyze the described effects of zoledronic acid on NFATc2 mutants in 
more detail, time kinetic experiments were conducted. Cells were exposed 
to 10 µM of zoledronic acid for up to 72 h and subcellular localization was 
analyzed by using immunofluorescence staining. As demonstrated in Fig. 
37A, a dramatic down regulation or proteasomal degradation of NFATc2-
∆SP2 can be observed exclusively in the nucleus as early as after 24 h, 











acid exposure. After 72 h of exposure, almost complete nuclear 
degradation of wild-type NFATc2 and NFATc2-∆SP2 was detected. In 
contrast, phospho mimicking NFATc2-pSP2 mutants were widely expressed 
in the nucleus and were not degraded. This was consistent with our 
readout in context to dose dependent effects of HDM2. Therefore, in the 
next experiment, we examined the role of zoledronic acid mediated 
degradation of wild-type (wt) NFATc2 and the two NFATc2 mutants in the 
presence of MG132. Again, exposure of cells to zoledronic acid resulted in 
proteasomal degradation of wild-type NFATc2 and NFATc2-∆SP2 protein, 
but this was completely reversed to control levels when cells were co-
treated with MG132. As expected, the NFATc2-pSP2 mutant showed 
complete resistance against zoledronic acid mediated proteasomal 





























Fig. 37. NFATc2 phosphorylation on S215/217/221 renders NFATc2 resistant against 
zoledronic acid mediated proteasomal degradation. (A) Immunofluorescence detection 
of the indicated wild-type (WT) HA-NFATc2, NFATc2-∆SP2, NFATc2-pSP2 and GFP control 
localization in MDA-MB-435 cells, after 18 h of transfection cells were treated with 
zoledronic acid (10 µM) at indicated time points. Cells were stained with anti-HA (red 
colour) and DAPI (blue) and GFP (green; original magnification for all: 63X). (B) MDA-MB-
435 cells were transfected with the indicated wild-type (WT) HA-NFATc2 or mutants 
NFATc2-pSP2 and NFATc2-∆SP2, after 18 h of transfection cells were treated with 
zoledronic acid (10 µM) for 32 h in complete media, then treated with MG132 (10 μM) for 
at least 12 h. After 72 h, cell lysates were immunoblotted with HA-antibodies. 
 
We therefore assayed the ability of HDM2 to interact with and to induce 
ubiquitination and degradation of NFATc2. Co-immunoprecipitation studies 
showed that HDM2 readily interacts with endogenous NFATc2 exclusively 
in the nucleus in untreated cells (Fig. 38A). Therefore, we tested the 
association between HDM2 and NFATc2 mutants respectively. Surprisingly, 
all three NFATc2 constructs interacted with HDM2, even NFATc2-pSP2 






Fig. 38. E3 ligase HDM2 physically interacts with NFATc2 mutants exclusively in the 
nucleus. (A) Nuclear lysates from MDA-MB-435 cells were immunoprecipitated using 
endogenous anti-NFATc2 and control (IgG) antibodies, and immunoblotted using the 
indicated antibodies. (B) MDA-MB-435 cells were co-transfected with the indicated wild-
type (WT) HA-NFATc2, NFATc2-∆SP2, NFATc2-pSP2 and vector control in combination with 
HDM2, as indicated. After 24 h of transfection, nuclear lysates were immunoprecipitated 
using anti-HDM2 and control (IgG) antibodies, and immunoblotted using the indicated 
antibodies. Total cell lysates used as a input control to reveal the expression of HDM2 and 
HA-NFATc2. 
 
However, to determine whether the interaction between NFATc2-pSP2, 
NFATc2-∆SP2 and wt NFATc2 with HDM2, promotes NFATc2 ubiquitination 
dependent degradation, cells were transiently transfected with all three 
NFATc2 constructs and treated with zoledronic acid in the presence or 
absence of MG132. Ubiquitination of wild type NFATc2 and NFATc2 
mutants was then examined. wt NFATc2 and NFATc2-∆SP2 were heavily 
ubiquitinated, whereas NFATc2-pSP2 was resistant to zoledronic acid 
mediated ubiquitination and proteasomal degradation (Fig. 39). Taken 
together, these data show that the E3 ligase HDM2 serves for NFATc2 
degradation, and the interaction between HDM2 and NFATc2 is 






Fig. 39. NFATc2 phosphorylation on S215/217/221 is resistant against zoledronic acid 
mediated ubiquitination. MDA-MB-435 cells were transfected with the indicated wild-
type (WT) HA-NFATc2 or mutants NFATc2-pSP2 and NFATc2-∆SP2, after 18 h of 
transfection cells were treated with zoledronic acid (10 µM) for 32 h, then treated with 
MG132 (10 µM) for at least 12 h. After 48 h of treatment, nuclear HA-NFATc2 
immunoprecipitates were immunoblotted with ubiquitin and HA-antibodies. 
 
4.8 THE LYSINES 684 AND 897 OF NFATc2-SPECIFIC 
C-TERMINUS ARE POTENT UBIQUITINATION SITES  
 
To assess the intracellular location of ubiquitination, we analyzed the 
individual ubiquitination sites within the N-terminus of NFATc2, we 
transfected constructs encoding HA-tagged NFATc2 or a deletion construct 
that covers the lysine rich N-terminus (NFATc2
1-460
) and vector control in 
MDA-MB-231 cells. Notably, NFATc2
1-460 
was not degraded, compared to 
wt NFATc2 after zoledronic acid treatment (Fig. 40B), suggesting that the C-
terminus of NFATc2 is crucial for ubiquitination. For further confirmation, 
cells were transfected with constructs encoding HA-tagged NFATc2, either 
wild type (wt) or NFATc2
1-460
. Interestingly, we found that wt-NFATc2 
underwent ubiquitination, whereas NFATc2
1-460 




in the presence of zoledronic acid and MG132, suggesting that the NFATc2 













Fig. 40. C-terminal deletion of NFATc2 prevents zoledronic acid mediated ubiquitination 
and degradation of NFATc2.  (A) Schematic representation of full length and C-terminus 
deletion of NFATc2 (B) MDA-MB-231 cells were transfected with either vector control or 
wild-type (WT) HA-NFATc2 and NFATc2
1-460
. After transfection, cells were treated with 
zoledronic acid (10 µM) for 72 h in serum media. Total lysates were immunoblotted with 
















control or (WT) HA-NFATc2 or NFATc2
1-460
. After 18 h of transfection cells were treated 
with zoledronic acid (10 µM) for 32 h in complete media, then treated with MG132 (10 
μM) for at least 12 h. After 48 h cells were lysed and HA- or IgG immunoprecipitates were 
immunoblotted with ubiquitin and HA-antibodies. 
 
However, despite the presence of multiple putative ubiquitin acceptor 
lysine residues, the NFATc2
1-460
 mutant showed resistance to zoledronic 
acid induced ubiquitination and proteasomal degradation. The lysine-poor 
C-terminal domain of NFATc2 contains two previously reported lysine 
residues (K 684 and K 897), which have most recently been identified as 
target sites for the small ubiquitin-related modifier SUMO (Terui et al., 
2004). Both lysines (K 684 and K 897) within the C-terminus region of 
NFATc2 fit to ubiquitination/sumoylation consensus sequences ( KXE: , 
hydrophobic; K, lysine; X, any amino acid; E, glutamic acid) and are 
conserved in both humans and mice, respectively (Fig. 41A and 41B). To 
determine if the lysine residues of NFATc2 are serving as ubiquitination 
sites, we focused on Lys-684 and Lys-897. Therefore, we mutated the 
residue in each of these two sites to Arginine. Immunoblot was performed 
after transfecting MDA-MB-231 cells with constructs encoding HA-tagged 




 in the 
presence of zoledronic acid. Interestingly, mutation of both the lysines in 
NFATc2
K684/897R
 completely rescued from the proteasomal degradation 
compared to wt NFATc2 (Fig. 41C); the individual mutation of NFATc2
K684
 
































Fig. 41. The C-terminal domain of NFATc2 contains two putative 
ubiquitination/sumoylation sites. (A) Sequence analysis showed that C-terminus of 
NFATc2 contains two consensus sequences for priming ubiquitination/sumoylation sites (
KXE: , hydrophobic; K, lysine; X, any amino acid; E, glutamic acid) on NFATc2 (B) 
Sumoylation/ubiquitination consensus sequences of NFATc2 are conserved in both human 
and mice (C) MDA-MB-231 cells were transfected with the indicated wild-type (WT) HA-




 expression constructs, then treated with 
zoledronic acid (10 µM) for 72 h. Total lysates were immunoblotted with anti-HA or β-
actin. 
 
To further analyze the effects of zoledronic acid on subcellular localization 
of wild type (wt) or NFATc2
K684/897R
 mutant by using immunofluorescence- 
staining, time kinetic experiments were performed as demonstrated in Fig. 
42A. Consistently, we saw wild-type NFATc2 nuclear degradation, whereas 
NFATc2
K684/897R
 mutant was widely expressed in the nucleus and not 
degraded. For further confirmation, IP experiments were performed after 
transfecting MDA-MB-231 cells with constructs encoding HA-tagged 
NFAC2_MOUSE 680 - PAIKTEPSDE 890 - PTGVTVKQEQ 





NFATc2, either wild type (wt) or NFATc2
K684/897R
 in the presence of 
zoledronic acid. As predicted, NFATc2
K684/897R
 mutant significantly reduced 
NFATc2 ubiquitination and proteasomal degradation as compared to wt 
NFATc2, suggesting that both the C-terminus lysines (K-684 and K-897) are 







Fig. 42. Zoledronic acid induces NFATc2 ubiquitination and proteasomal degradation via 
two C-terminal lysines. (A) Immunocytological detection of the indicated wild-type (WT) 
HA-NFATc2, NFATc2
K684/897R 
mutant and GFP control localization in MDA-MB-435 cells, 




points. Cells were stained with anti-HA (red) and DAPI (blue) and GFP (green; original 
magnification: 63X). (B) The indicated HA-NFATc2 constructs was transfected in MDA-MB-
231 cells. After 18 h of transfection cells were treated with zoledronic acid (10 µM) for 32 
h in complete media, then treated with MG132 (10 μM) for at least 12 h. After 48 h cells 
were lysed and NFATc2 immunoprecipitates were immunoblotted with ubiquitin and HA-
antibodies.  
 
To further determine the relevance of these two K-684 and K-897 lysines in 
the highly unstable NFATc2-∆SP2 mutant, we mutated these two lysine 
residues to Arginine. Immunoblot was performed after transfecting MDA-
MB-435 cells with constructs encoding HA-tagged NFATc2, either wild type 
(wt) or NFATc2-ΔSP2
K684/897R
 in the presence of zoledronic acid. 
Interestingly, we found that NFATc2-ΔSP2
K684/897R 
was resistant to 
proteasomal degradation by zoledronic acid compared with the NFATc2-
∆SP2 mutant (Fig. 43).  
 
Fig. 43. The lysines K-684 and K-897 are crucial for zoledronic acid mediated proteasomal 
degradation. MDA-MB-435 cells were transfected with the indicated NFATc2-∆SP2 and 
NFATc2-ΔSP2
K684/897R
 constructs, then treated with zoledronic acid (10 µM) for 72 h. Total 
lysates were immunoblotted with anti-HA- or β-actin antibodies. 
 
Next, we examined the effects of zoledronic acid on subcellular localization 
by using immunofluorescence staining. As demonstrated in Fig. 44, a clear 




the nucleus as early as 24h, and as expected, the NFATc2-ΔSP2
K684/897R 
mutant was widely expressed in the nucleus and not degraded in 
comparison with the NFATc2-∆SP2 mutant. Taken together, these data 




Fig. 44. Two lysine residues, K-684 and K-897, rescue the effect of zoledronic acid 
mediated degradation of NFATc2 (∆SP2). Immunofluorescence detection of the indicated 
NFATc2-∆SP2, NFATc2-ΔSP2K684/897R and GFP control localization in MDA-MB-435 cells, 
after 18 h of transfection cells were treated with zoledronic acid (10 µM) at indicated time 
points. Cells were stained with anti-HA (red) and DAPI (blue) and GFP (green; original 
magnification: 63X). 
 
Recently, it has been shown that post-translational protein modification 
with small ubiquitin-related modifier (SUMO), triggers ubiquitin mediated 
proteasomal degradation (Breitenbach et al., 2008). To examine whether 
ubiquitination on NFATc2
K684/897R
 mutant is sumoylation dependent, IP 
experiments were performed after transfecting MDA-MB-231 cells with 
constructs encoding HA-tagged NFATc2, either wild type (wt) or 
NFATc2
K684/897R
, Flag-Sumo-1, E2 ligase Ubc-9 or vector control in the 
presence of zoledronic acid. Wt NFATc2 produced Sumo-specific bands in 
untreated cells whereas after treatment with zoledronic acid, Sumo-bands 
disappear. Significant ubiquitination on wt NFATc2 compare to untreated 
cells (Fig. 45) could be seen. Taken together, we neither see sumoylation 
nor does ubiquitination in NFATc2
K684/897R
















Fig. 45. Zoledronic acid induces NFATc2 ubiquitination and proteasomal degradation via 
two C-terminal lysines. MDA-MB-435 cells were co-transfected with the wild-type (WT) 
HA-NFATc2 or mutant NFATc2
K684/897R
 or indicated Flag-Sumo-1 or Ubc-9 constructs. After 
18 h of transfection cells were treated with zoledronic acid (10 µM) for 48 h in complete 
media, then lysates were analysed by HA-NFATc2 or IgG immunoprecipitates and 
immunoblotted with Flag-Sumo-1, ubiquitin and HA-antibodies. 
 





5.1 ZOLEDRONIC ACID EXERTS STRONG 
ANTITUMORIGENIC ACTIVITIES IN BREAST AND 
PANCREATIC CANCER 
 
Third generation nitrogen-containing bisphosphonates (N-BPs) such as 
zoledronic acid, are a class of antiresorptive drugs used to treat the benign 
and malignant skeletal diseases related with increased bone loss, e.g. 
Paget’ disease, osteoporosis and metastasis related osteolysis (Rodan et 
al., 2002; Russell et al., 1999. After targeting the skeleton because of their 
high affinity for bone mineral, N-BPs primarily act by inhibiting osteoclastic 
bone resorption, thus alleviating the tumor-associated bone disease 
(Clezardin et al., 2005). However, in recent years, it has become clear from 
studies in preclinical models that these drugs also have potential antitumor 
activity.  
 
In vitro and in vivo studies revealed inhibition of cancer cell proliferation, 
adhesion and invasion and demonstrated successful reduction of tumor 
outgrowth in mice bearing subcutaneous tumors derived from various 
epithelial tissues (Boissier et al., 2000; Pluijm et al., 1996). Concordantly, 
growing data from clinical trials emphasized strong tumor suppressor 
capacities of zoledronic acid and encourages its application in both 
adjuvant and palliative settings. A most recently published multi-center 
study supports application of the drug in an adjuvant setting and showed 





tumor recurrence and increases disease-free survival of patients with early 
breast cancer stages who underwent surgery (Gnant et al., 2009).  
 
Though the therapeutic impact of zoledronic acid  on cancer growth is now 
well established, it is still unclear, how these tumor suppressor activities 
are mediated in molecular level. We therefore conducted the presented 
study with the ambitious aim to identify signaling and transcription 
pathways with key roles in zoledronic acid growth suppression. We focused 
our attention on breast and pancreatic cancer and combined a battery of in 
vitro and in vivo approaches to address this issue.  
 
As predicted from previous studies, we could show that zoledronic acid 
treatment indeed exerts strong growth suppressor functions in human 
cancer cell lines and in xenograft mice models as well. In detail, we 
observed that zoledronic acid effectively blocks cancer cell proliferation in 
most of the tested cell lines. Growth inhibition was apparent 24 h post 
treatment and reached a maximal effect 72 h following administration of 
the drug. Depending on the cell type, zoledronic acid applied at a dosage of 
10 µM caused a 60-80% reduction of cell growth in most of the tested 
cancer cell lines, and this effect originated from a cell cycle arrest, as 
evidenced by a shift of cells from S to G1 phase of the cell cycle. Moreover, 
G1 arrest was paralleled by a reduction of cyclin D1 expression and its 
partner kinases CDK4 and CDK6, as evidenced by western blot analysis. We 
then analyzed whether the in vitro growth suppression also holds true in a 
biological system and assessed the therapeutic effect of the new 
generation bisphosphonate in a xenograft tumor mice model following 
subcutaneous injection of IMIM-PC1 pancreatic cancer cells. These 
experiments confirmed  the in vivo potential of zoledronic acid to suppress 







5.2 ZOLEDRONIC ACID TARGETS NFATc2 TO 
MEDIATE GROWTH SUPPRESSION IN CANCER 
 
NFATc2 belongs to the nuclear factor of activated T-cells (NFAT) family of 
transcription factors which are primarily recognized for their roles in T-
lymphocyte activation (Crabtree et al., 1999; Crabtree et al., 2002; Rao et 
al.,1997). NFAT (nuclear factor of activated T cells) transcription factors 
were originally described as nuclear proteins that bind to and control the 
activity of the interleukin 2 (IL-2) promoter and further lymphokine 
promoters/ enhancers in T lymphocytes (Shaw et al., 1988),. Among the 
five members of the NFAT factor family the activity of four NFATc proteins 
(NFATc1, c2, c3 and c4) is controlled by the Ca++/calmodulin-dependent 
phosphatase calcineurin (CN) that, by dephosphorylating numerous sites 
within the regulatory region of NFAT, stimulates cytosolic-nuclear 
translocation. 
  
In the nucleus, NFAT interacts with the A/TGGAAA consensus sequence of 
target gene promoters through a common DNA-binding
 
domain (DBD) that 
has a moderate sequence similarity to the
 
DBD of the Rel family of 
transcription factors (Hoey et al., 1995; Masuda et al., 1995; Rao et al., 
1997). NFAT proteins can either activate or repress the transcription of 
their target genes, depending on the cell-type, the target promoter 
sequence they bind to, and the nuclear context at a given time (Macian et 
al., 2005; Rao et al., 1997). NFAT proteins also share a regulatory
 
conserved 
N-terminal region called the NFAT homology region
 
(NHR) that harbours 
multiple sites for post-translational modifications and serves as a structural 
platform for interaction with co-activators and repressor proteins such as 
p300/CBP, HDACs and other chromatin remodelling proteins (Clipstone et 
al., 1992; Shibasaki et al., 1996; Lopez-Rodriguez et al., 1999; Downes et 





terminal region, and is achieved by the action of export kinases, including 
CK-2 and the GSK3β kinase (Kehlenbach et al., 2000; Beals et al., 1997). 
Thus, the activity of NFAT proteins is mainly regulated on the level of 
phosphorylation and subcellular distribution. However, although primarily 
identified and characterized in T-cells, NFAT proteins are by no means 
restricted to the immune system.  
 
In fact, NFAT proteins participate in the regulation of genes influencing the 
development and differentiation of numerous mammalian cells and 
tissues. It has been shown, for instance, that NFAT proteins control 
multiple steps in myogenesis, chondrocyte differentiation and the 
development of the cardiovascular system (Crabtree et al., 2002; Im et al., 
2004). Recent evidence also suggests that NFAT proteins, and in particular 
NFATc1 and NFATc2, control important aspects of carcinogenesis and 
influence cancer cell proliferation and apoptosis, and regulate peripheral 
vascular development during angiogenesis (Caetano et al., 2002; Baksh et 
al., 2002; Graef et al., 2003; Buchholz et al., 2006). Consistent with 
previous findings, we found overexpression of the factor in a series of 
breast and pancreatic cancer tissues and in all cancer cell lines. Our 
proliferation assays combined with knockdown approaches revealed strong 
growth promoting function of NFATc2 in these cancer types and 
demonstrated a profound block of cell proliferation and reduced 
expression of the G1-cell cycle promoting genes cyclin D1, CDK4 and CDK6 
upon genetic silencing of the factor.  
 
Most importantly and similar to our findings in animal studies, zoledronic 
acid treatment caused a dramatic reduction of NFATc2 expression and 
activity in cancer cells. The loss of NFATc2 was time-and dose-dependent 
and was exclusively found in cancer cells responsive to growth inhibition by 





proliferative functions of NFATc2 and pointed at a potentially critical role of 
its silencing in zoledronic acid induced growth suppression.  
 
 
Fig. 46. Shematic representation of the NFAT domains. The regulatory domain is where 
calcineurin binding and dephosphorylation/phosphorylation occur. The red circles indicate 
phosphate groups that can be removed by calcineurin and the black circle on the SRR-2 
domain indicates a phosphate group that can not be dephosphorylated by calcineurin. The 
A and B motifs indicate the calcineurin binding sites CnBP-A and CnBP-B (adapted from 
Hogan et al., 2003). 
 
5.3 ZOLEDRONIC ACID DISRUPTS A NUCLEAR GSK3β 
NFAT STABILIZATION PATHWAY IN CANCER 
 
Next, we performed an extensive series of cellular, biochemical and 
molecular studies to uncover the underlying mechanisms of NFATc2 
inactivation by the bisphosphonate. 
  
These studies revealed that decreased NFATc2 levels resulted from 
accelerated protein turnover rather than inhibition of gene expression. In 
fact, RT-PCR analyses showed unchanged level of mRNA expression upon 
treatment. However, application of MG-132, a cell-permeable and 
reversible inhibitor of proteasomal degradation, abolished NFATc2 down-
regulation in cancer cells and this effect was paralleled by strong 





assays to control for the cellular distribution pattern of NFATc2 and to 
identify the cellular site of its degradation. In agreement with previous 
reports, we found NFATc2 distributed in both compartments and in 
different activation and phosphorylation status. Treatment with this 
compound, however, exclusively targeted NFATc2 when present in the 
nucleus and in its unphosphorylated, active form. Hyperphosphorylated 
NFATc2, on the other hand, was refractory to the bisphosphonate and thus 
remained stable, even after application of high doses. From these 
experiments reveal that the level of phosphorylation not only regulates 
NFATc2 activity and cellular localization (as described previously) but also 
determines its stability level and responsiveness to zoledronic acid.  
 
5.4 EXISTENCE AND TARGETING OF A NUCLEAR 
GSK3β-NFATc2 STABILIZATION PATHWAY IN 
CANCER 
 
The next step was to identify the NFATc2 kinase responsible for 
phosphorylation and stabilization of the transcription factor. We focused 
on glycogen synthase kinase 3β (GSK3β), which is a serine/threonine kinase 
with key functions in the regulation of various vital cellular processes 
ranging from glycogen metabolism and insulin signaling to embryonic 
development and carcinogenesis (Roberts et al., 2004; Henriksen et al., 
2006; Lee et al., 2007). Depending on the tumor type, the subcellular 
distribution and the level of its activity, GSK3β can exert tumor suppressor 
activities as well as oncogenic functions. In pancreatic cancer, recent 
observations by Billadeau and coworkers suggested strong pro-proliferative 
functions of GSK3β (Ougolkov et al., 2006). Increased expression and 





PanIN lesions, and with increased frequency and intensity in advanced 
cancers with a high proliferation rate.  
 
Years ago, GSK3β was described as a nuclear export kinase that induces 
phosphorylation dependent nuclear-to-cytoplasmic translocation of 
NFATc2 in T-cells (Beals et al., 1997). In a very recent study, it has been 
postulated that GSK3β not only controls cellular shuttling but also the 
protein expression level of NFATc2 (Yoeli-lerner et al., 2009). It has been 
shown, for instance, that AKT-signaling through inhibition of GSK3β induces 
NFATc2 turnover in breast cancer cells, and this effect is ultimately linked 
to inhibition of tumor cell migration by activation of the Pi3K-AKT pathway 
(Yoeli-lerner et al., 2005). Prompted by these recent findings, we 
investigated whether GSK3β stabilizes NFATc2 in proliferating cancer cells 
and if so, whether this function is aimed by zoledronic acid.   
 
We first analyzed the expression pattern of GSK3β in cancer and found high 
levels of the kinase in both pancreatic cancer and breast cancer tissues and 
cell lines and in co-localization with NFATc2. Like NFATc2, GSK3β was 
distributed throughout the cells with active fractions in the cytosolic and 
the nuclear compartment. Treatment with zoledronic, however, caused a 
dose-dependent inhibition of GSK3β kinase activity in the nucleus and this 
effect was paralleled by an accretive loss of NFATc2. Since introduction of a 
constitutive active GSK3β constructs antagonized NFATc2 degradation, we 
assumed the existence of a nuclear GSK3β-NFATc2 stabilization pathway 
that is disrupted by this compound. GSK3β phosphorylates its target 
substrates preferentially at the consensus sequence S/T-X-X-X-Phospho-
S/T, where the first S/T residue is the target for GSK3β phosphorylation 







Sequence analysis of NFATc2 revealed the presence of three consensus 
GSK3β serine phosphorylation residues (S213, S217 and S221) located in 
the SP2 motif of the NFAT homology region. These phosphoserine residues 
are conserved among species and match with the previously characterized 
“phospho-degron” sequence through which GSK3β targets a subset of 
transcriptional regulators (e.g. c-Myc, SRC-3 and Notch-1) for 
phosphorylation dependent ubiquitination. The “phospho-degron” site is 
therefore recognized as a key identification code for GSK3β to label 
substrates for their subsequent turnover (Wu et al., 2007). For instance, 
phosphorylation of S505 by GSK3β marks the SRC-3 co-activator of STAT 
signaling for efficient ubiquitin transfer and rapid proteasomal 
degradation. Similarly, c-Myc phosphorylation by GSK3β at Threonine (58) 
provides the signal for its subsequent turnover by the proteasomal 
machinery (Gregory et al., 2003). We proposed that GSK3β also targets 
NFATc2 through the conserved “phospho-degron” sequence, in this case 
however, to protect the factor from ubiquitination and recognition by the 
26S proteasome.  
 
To verify our model, we generated NFATc2 mutations in which the 
“phospho-degron” elements were modified through substitution of 
S213/217/221 for either Alanine (NFATc2-ΔSP2) or Aspartic acid (NFATc2-
pSP2). We then tested their remaining stability and responsiveness to 
zoledronic acid. These experiments performed in breast and pancreatic 
cancer cells confirmed the significance of the “phospho-degron” sites and 
demonstrated a high protein turnover of NFATc2 following mutational 
inactivation of the GSK3β phosphoserines. Moreover, introduction of 
GSK3β resistant mutations rendered NFATc2 highly unstable, led to 
reduced lifetime duration and caused accelerated degradation of the factor 
upon treatment with by zoledronic acid. The significance of  
phosphorylation by GSK3β  was underscored by phospho-mimicking 





the transcription factor from nuclear ubiquitin transfer and degradation by 
the compound.  
 
Taken together, these experiments identified the presence of a nuclear 
GSK3β-NFATc2 stabilization pathway that is aimed and disrupted by 
zoledronic acid to mediate anti-tumoral functions. Moreover, these 
findings contribute to a better understanding of how GSK3β and NFATc2 
cooperate in tumor cell proliferation. It will be of great interest to identify 
under which conditions, GSK3β favors stabilization over degradation of key 
cell cycle regulators in cancer, and to verify whether this decision happens 
in a tumor-type dependent manner or is regulated by the nuclear context. 
It will also be of interest to investigate the anti-tumorigenic capacity of 
zoledronic acid in tumor types other than pancreatic and breast cancers, 
and to analyze whether the drug targets additional pro-proliferative 
pathways other than the GSK3β-NFAT signaling cascade to suppress tumor 
growth. 
 
5.5 CHARACTERIZATION OF ZOLEDRONIC ACID 
MEDIATED NFATc2 UBIQUITINATION IN CANCER 
 
To better understand the ubiquitination of NFATc2 which leads to 
degradation of this protein, we performed sequence analysis which 
revealed the presence of multiple putative ubiquitin acceptor lysine 
residues within the N-terminal domain.   
 
Consequently, to determine whether the N-terminus is target for 
ubiquitination, we transfected cells with wt-NFATc2 or a deletion construct 
that encompasses the lysine rich N-terminus (NFATc2
1-460
). Surprisingly, 





treatment with the compound failed to induce ubiquitination and 
degradation of NFATc2
1-460
. Analysis of the C-terminus, on the other hand, 
displayed two additional lysines residues (K-684 and K-897) which have 
most recently been identified as target sites for the small ubiquitin-related 
modifier SUMO (Terui et al., 2004). SUMO-1 shares similarity with ubiquitin 
and can be attached covalently to lysine residues in a process that is 
mechanically analogous to ubiquitination. Sumoylation involves the 
formation of an iso-peptide bond between the carboxy-terminal Gly of 
SUMO and the -amino group of a lysine side chain in the target protein 
(Hay et al., 2005).  
Prompted by recent findings indicating that SUMO and ubiquitin can 
actually target the same lysine residues of common substrates, we tested 
the relevance of K-684 and K-897 in NFATc2 ubiquitination. Double 
mutation of both lysines (NFATc2
K684/897R
) indeed prevented the transfer of 
ubiquitin and consequently abolished degradation upon treatment, 
indicating that K-684/897 ubiquitination is key for the NFATc2 turnover. In 
support of this conclusion, the highly unstable NFATc2-ΔSP2
 
mutant 
became fully resistant to zoledronic acid upon mutational disruption of the 




Ubiquitination is arranged through the action of E3 ligases which conjugate 
ubiquitin to target proteins and thus label them for subsequent 
degradation by the 26S proteasome. HDM2, the human homolog of the 
RING-finger ligase MDM2 (murine double minute 2) is often present at 
increased levels in tumors with wild-type p53 and likely serves as an 
alternate mechanism to disrupt the p53 pathway in developing cancer cells 
(Haupt et al., 1997; Fang et al., 2000). However, HDM2 also targets 
numerous other substrates, particularly in p53 mutant cancer cells and 
when present at elevated levels (Iwakuma et al., 2003; Lozano et al.,2003). 
Overexpression of HDM2 can result from gene amplification, increased 





glioblastomas and malignant melanomas but also in pancreatic and breast 
cancer (Haupt et al., 1997; Kubbutat et al., 1997; Honda et al., 1997).  
 
We questioned whether HDM2 is the E3-ligase responsible for zoledronic 
acid mediated NFATc2 ubiquitination and degradation. Weak to moderate 
HDM2 expression levels were found in all tested cell lines. Surprisingly, 
however, zoledronic acid dose-dependently enhanced the total amount 
and nuclear expression of endogenous HDM2 and this effect correlated 
inversely to the progredient loss of NFATc2. Moreover, we were able to 
demonstrate that HDM2 physically interacts with and induces degradation 
of NFATc2 in the nucleus and when present in its unphosphorylated 
version. Phosphorylated NFATc2, on the other hand, was proven to be 
resistant to HDM2 – as it is to zoledronic acid – and thus remains 
unaffected and stable. Finally, the crucial role of HDM2 in zoledronic acid 
mediated NFATc2 degradation and growth suppression is highlighted by 
HDM2 silencing experiments, demonstrating that HDM2 depletion not only 
obviates NFATc2 degradation and the consequent reduction of G1-phase 
promoting genes, but impairs growth retardation by the compound. 
 
Therefore, this data identified HDM2 as the molecular machinery 
responsible for the ubiquitin transfer to unphosphorylated NFATc2 in 
response to zoledronic acid. 
 
5.6 SIGNIFICANCE AND CONCLUSION OF THIS 
DISSERTATION 
 
Taken together, this study identifies the pro-proliferative transcription 
factor NFATc2 as a master target of zoledronic acid in cancer. We show 





mediated cancer growth suppression. Mechanistically, zoledronic acid 
inhibits nuclear GSK3β kinase and thereby impairs phosphorylation-
dependent NFATc2 stabilization. In addition, bisphosphonate increases the 
accumulation of E3-ligase HDM2 in the nucleus of cancer cells to target 
unphosphorylated NFATc2 for ubiquitin transfers subsequent proteasomal 
degradation, resulting in a halt of cancer cells at the G1-cell cycle phase.  
 
From the medical point of view, this work constitutes a highly 
descriptive molecular study on the mechanisms of action of zoledronic 
acid tumor suppression activity. Our study thus contributes to a better 
understanding at molecular and biochemical basis underlying one of the 
most promising and exciting new treatment for malignant disease. 
Biochemically, we outlined a defined pathway mediating the effects of 
zoledronic acid, discovering novel mechanisms for growth suppression 
that involucrate several molecules which can be potential additional 
targets for therapies which may complement zoledronic acid treatment. 
For instance, treatment with this drug lead to an accumulation of nuclear 
HDM2 and inhibition of GSK3β kinase in order to disrupt phosphorylation-
dependent NFATc2 stabilization. HDM2 targets unphosphorylated NFATc2 
for ubiquitin transfer and induces its proteasomal degradation, resulting 
in loss of NFAT transcriptional responses and a block of cancer cell 
growth. 
 
Therefore, this study contributes to both the basic biochemical 
knowledge on cell cycle arrest but also reveals medical information of 
paramount importance to patients by providing a well-characterized 








































Fig. 47. Model showing NFATc2 stabilization in untreated cancer cells. GSK3β mediated 
phosphorylation of three serine residues protects NFATc2 from HDM2 mediated 




Fig. 48.  Model showing the effect of zoledronic acid mediated ubiquitination and 
proteasomal degradation of NFATc2 in cancer cells. Loss of GSK3β activity by zoledronic 
acid, exposed two Lysines K-684 and K-897 of NFATc2 for ubiquitination and proteosomal 
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aa                 Amino acid 
Ab     Antibody 
AP1     Activating protein-1 
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ATCC     American type culture collection 
bp      Base pair 
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BSA      Bovine serum albumine 
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c.a.     Constitutive active 
CBP      CREB binding protein 
CDK     Cyclin dependent kinase 
CK-1     Casein kinase-1 
CsA      Cyclosporin A 
DAPI      4’,6-Diamidino-2-phenylindole 
DBD      DNA binding domain 
DMEM     Dulbecco´s Modified Eagle Medium 
DMSO      Dimethylsulfoxide 
DNA     Deoxyribonucleic acid 
Dnase     Deoxyribonuclease 
DTT      1,4 Dithiothreitol 
E1      SUMO or ubiquitin activating enzyme 
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      enzyme 
E3      SUMO or ubiquitin ligase 
E.coli     Escherichia coli 




E2F     Electro-acoustic 2 Factor 
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IB     Immunoblot 
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S-phase     Synthesis phase 
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SUMO      Small ubiquitin like modifier 
TE      Tris-EDTA 
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